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Summary 
The classical endocrine renin-angiotensin aldosterone system (RAS) plays an 
important role in blood pressure and fluid balance regulation. Important effectors 
of the RAS are small bioactive peptides like angiotensin II (Ang 1-8) or Ang 1-7. 
The possibility to reliably quantify the low abundance RAS peptides in serum 
using a mass spectrometry based method opened up new opportunities to 
investigate their role as possible biomarkers in patients treated with cardiovascular 
drugs that modulate the RAS cascade. In a pilot study in healthy individuals, RAS 
peptide concentrations were quantified under normal conditions and after 
administration of approved drugs that inhibit key enzymes of the  RAS (renin, 
angiotensin-converting enzyme) or block the effect of Ang 1-8 (angiotensin 
receptor antagonists). Changes reflecting the mechanism of action of the different 
drugs were evident within a few hours after single dose administration. Based on 
these promising pilot data, the goal of the subsequent three clinical studies 
performed in the framework of this dissertation was to systematically characterize 
the RAS peptide profiles in normotensive healthy subjects as well as in patients 
with arterial hypertension. The work should contribute to a better understanding of 
the RAS peptides and investigate their possible role as biomarkers for patients 
under treatment with RAS modulating drugs. 
In the first study, we assessed RAS peptide concentrations after single and 
repeated oral administration of the renin inhibitor aliskiren, the ACE inhibitor 
enalapril, and the angiotensin receptor antagonist losartan in healthy normotensive 
subjects. RAS peptide profiles showed drug-specific changes which directly 
reflected the mechanism of action of the different RAS inhibitors after single and 
multiple dose treatment for one week. While inhibition of renin decreased 
downstream RAS peptide concentrations, the ACE inhibitor caused a decrease of 
the ACE products Ang 1-8 and Ang 1-5. The angiotensin receptor antagonist on 
the other hand caused an increase of upstream Ang 1-10 and Ang 1-8 mainly by 
enhanced renin-feedback. Overall, the data suggested that RAS peptide profiles 
could be of value for the assessment of patients under RAS inhibitor therapy.  
In the second study, the potential of drug-specific profiles found in healthy 
normotensive subjects as possible biomarkers were assessed in patients before and 
after start of monotherapy for arterial hypertension. Patients were randomized to 
four groups and RAS peptide concentrations were assessed after 4 weeks of 
consecutive oral treatment with intermediate or high doses of the ACE inhibitor 
  
perindopril, the angiotensin receptor antagonist olmesartan, the calcium channel 
antagonist amlodipine or the thiazide diuretic hydrochlorothiazide. These four 
drugs are used as first line treatments in clinical practice. After treatment with the 
ACE inhibitor and the angiotensin receptor antagonist, RAS peptide profiles again 
showed the drug-specific changes observed in healthy normotensive subjects. The 
changes observed with the calcium channel antagonist and the thiazide diuretic 
were similar but less pronounced as for the ones observed after an angiotensin 
receptor antagonist treatment.  The study showed that the drug-specific changes are 
preserved for at least 8 weeks of treatment. 
Next it was of interest whether drug-specific changes could also be detected 
in patients under combination drug treatment. In the third study we therefore 
investigated RAS peptide profiles in patients with uncontrolled arterial 
hypertension, as such patients per definition are treated with at least three different 
antihypertensive drugs. With insufficient therapeutic response despite receiving 
combination drug treatment, patients with treatment resistant arterial hypertension 
belong to the most complex patient group. However, these patients are at great risk 
of stroke, myocardial infarction, heart failure, and/or chronic kidney disease and 
the benefits of successful treatment are substantial. Even in this heterogeneous 
patient group, the drug-specific RAS peptide profile changes observed in healthy 
normotensive subjects and patients under antihypertensive monotherapy were 
maintained. Data generated by this study suggest that RAS peptide profiles might 
also be useful in other patient populations treated with cardiovascular drug 
combinations.  
In conclusion, data generated by our studies showed a correlation between 
RAS peptide concentrations and treatment with an ACE inhibitor or angiotensin 
receptor antagonist in normotensive healthy subjects as well as in patients with 
arterial hypertension under monotherapy or in patients with uncontrolled 
hypertension with a combination drug treatment. Taken together, RAS peptide 
profiles as biomarkers for the assessment of drug adherence and (in combination 
with drug concentrations in plasma) true drug resistance as well as their potential 
usefulness in the guidance of antihypertensive treatment in patients with 
insufficient treatment response merits further investigation. 
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ACE Angiotensin-I-converting enzyme 
ACE2 Angiotensin-I-converting enzyme 2 
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1  Introduction 
1.1 Arterial Hypertension 
Arterial hypertension is defined as a systolic blood pressure (SBP) ≥140 mmHg or 
a diastolic blood pressure (DBP) ≥90 mmHg.[1, 2] Arterial hypertension is an 
important cardiovascular (CV) risk factor, leading to heart attacks and strokes. The 
incidence of arterial hypertension increases with age. Worldwide approximately 
one billion people are affected and about nine million people die from it every 
year. The prevalence of arterial hypertension increases from 18 to 30% in America, 
Western Pacific Region, Europe, South-East Asia Region, Eastern Mediterranean 
Region and Africa. Although there is no huge difference in mean prevalence 
between developed and developing countries, mortality rates of cardiovascular 
disease (CVD) are higher in low-income countries than those of industrialized 
nations.[3] In Switzerland, limited data are available on the prevalence of 
hypertension as there is no survey covering whole Switzerland. According to data 
provided by the Federal Office of Statistics in Switzerland, the overall prevalence 
of hypertension was around 18% in 2012, with a substantial increase with age. 
Compared to data from 1992, there was a noticeable increase in prevalence over 
the two past decades, especially in men. From 1992 to 2012, prevalence of arterial 
hypertension in Swiss men aged 55 – 64 years, 65 – 74 years and older than 75 
years, rose from 21.9%, 32.0% and 30.3% to 31.1%, 48.5% and 50.3%, in Swiss 
women from 21.8%, 35.7% and 41.3% to 23.2%, 38.5% and 56.9%, respectively 
(Source: Federal Statistical Office, Swiss Health Interview Survey 2012). 
Furthermore, CVD are the most common cause of death in Switzerland, 
accounting for 30.6% of deaths in men and 34.8% of deaths in women (Source: 
Federal Statistical Office, Swiss causes of death statistics 2014). 
1.1.1 Management of Arterial Hypertension 
At the University Hospital Basel, antihypertensive drug treatment follows current 
ESH guidelines for management of arterial hypertension.[4] This includes 
confirmation of diagnosis of hypertension by a 24 hour ambulatory blood pressure 
monitoring, detection of causes of secondary hypertension and assessment of total 
CV risk which is determined by blood pressure (BP) level, CV risk factors, 
asymptomatic organ damage, the presence of diabetes, asymptomatic CVD or 
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chronic kidney disease. Depending on BP level and total CV risk, antihypertensive 
therapy is started with a single agent or with a two-drug combination. In case of 
mild BP elevation and low or moderate total CV risk, initial treatment is a 
monotherapy at moderate dose with a subsequent increase in drug dose if BP goal 
is not achieved. Target BP should be at least < 140/90 mmHg in all hypertensive 
patients. If BP goal is not achieved with a full dose monotherapy, a two-drug 
combination is required. In case of marked BP elevation or when total CV risk is 
high or very high with mild BP elevation a two-drug combination at low doses 
should be preferred for initial treatment. If BP goal is not achieved with a two-drug 
combination at full dose, a third drug is added. Suitable and recommended 
antihypertensive drug classes for treatment initiation are angiotensin-converting 
enzyme inhibitors, angiotensin receptor antagonists, calcium antagonists, diuretics 
and beta-receptor antagonists. Lifestyle modification such as healthy diet, sodium 
and alcohol restriction, regular physical activity, smoking cessation and weight 
reduction where necessary should always be performed in addition to any 
antihypertensive drug treatment. 
1.1.2 Treatment-Resistant Hypertension 
Resistant hypertension is defined as blood pressure that remains above goal in spite 
of concurrent use of 3 antihypertensive agents at optimal doses, including a 
diuretic or BP is controlled with four or more medications.[5] The true prevalence 
of treatment-resistant hypertension is difficult to quantify because differentiation 
between true resistant and pseudo-resistant hypertension is difficult. True 
resistance refers to a true drug resistance, where reasons for a pseudo-resistant 
hypertension are white-coat hypertension, BP elevating co-medications, poor 
adherence, insufficient drug therapy, or secondary causes such as obstructive sleep 
apnea or primary aldosteronism. Although the true prevalence of apparent 
resistance is unknown, several studies indicate that a considerable number of 
patients do not reach BP goals and thus uncontrolled hypertension is a clinical 
problem.[5-8] Patients with uncontrolled arterial hypertension are at greater risk of 
stroke, myocardial infarction, heart failure, and/or chronic kidney disease and the 
benefits of successful treatment are substantial.[9, 10] Moreover, literature 
indicates that non-adherence is one of the major causes of uncontrolled 
hypertension and therefore treatment failure.[11, 12] In patients referred from 
primary care physicians to a tertiary centre for further work-up of uncontrolled 
hypertension, partial or complete non-adherence was found in more than half of 
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the patients.[13] Detection and treatment of uncontrolled hypertension due to non-
adherence is important to improve the management of these patients but few tools 
exist to accurately and routinely detect it. 
1.2 Renin-Angiotensin System 
The renin-angiotensin system (RAS) plays an important role in the regulation of 
blood pressure.[14] Angiotensin II (Ang 1-8) is the main effector peptide of the 
classic RAS. It is formed by c-terminal cleavage of two amino acids from 
Angiotensin I (Ang 1-10) by the angiotensin-I-converting enzyme (ACE).[15] The 
effects of Ang 1-8 mediated by binding of Ang 1-8 to the angiotensin type I 
receptor (AT1) include vasoconstriction, stimulation of aldosterone and 
antidiuretic hormone release, inflammation, cardiac hypertrophy, vascular 
proliferation, and oxidative stress. This activation of the classical ACE – Ang II –
AT1 axis of the RAS has been associated with hypertension. The Effects mediated 
by binding of Ang 1-8 to the angiotensin type II receptor (AT2), include 
counter-regulatory effects such as vasodilation and anti-inflammatory, 
pro-apoptotic, anti-proliferative and anti-oxidative stress effects.[16] The binding 
affinity of Ang II for the two AT receptors is comparable, but AT1 is ubiquitously 
expressed in the CV system while AT2 is low expressed in healthy adults and can 
be modulated by pathological states such as hypertension or stroke.[17] In 2000, a 
tissue specific human homologue of ACE, called angiotensin-I-converting enzyme 
2 (ACE2) was described [15, 18] and subsequently the alternative axis ACE2 – 
Ang 1-7 – Mas has been established.[19] In this axis, Ang 1-7 is formed by 
cleavage of a single amino acid from the c-terminus of Ang 1-8 by ACE2.[15] The 
effects of Ang 1-7 mediated by binding of Ang 1-7 to the G-protein coupled 
receptor MAS [20] include opposing effects to the classic RAS axis, such as 
vasodilation, vascular protection and anti-proliferation as well as anti-fibrinogenic, 
anti-thrombogenic and anti-arrythmogenic effects.[20-22] Studies suggest a 
contribution of the ACE2 – Ang 1-7 – Mas axis in the evolution of hypertension 
and a reduction in the expression and activity of Ang 1-7 may be a critical factor in 
mediating the progression of CVD.[23] Figure 1 summarizes the minor and major 
degradation pathways of Ang 1-10. 
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ACE = Angiotensin-I-converting-enzyme 1 
ACE2 = Angiotensin-I-converting-enzyme 2 
AP = Aminopeptidase 
NEP = Neutral endopeptidase 
(1-8) = Angiotensin II,  angiotensin 1-8 
AT1-R = Angiotensin II type 1 receptor 
MAS = Mas receptor 
 
RI = Blocked by renin inhibitors 
ARB = Blocked by angiotensin receptor antagonists 
ACEi = Blocked by ACE inhibitors 
Figure 1: Degradation pathway of angiotensinogen. The numbers in brackets indicate the 
number of amino acids (figure provided by Marko Poglitsch, Attoquant Diagnostics GmbH). 
According to their different mechanisms of action, CV drugs such as renin 
or ACE inhibitors, or angiotensin receptor antagonists will cause characteristic 
concentration changes of Ang 1-10, Ang 1-8 and possibly also of smaller 
downstream RAS peptides. In recent years, several MS based methods have been 
developed for the quantification of angiotensin peptides in human plasma.[24-28] 
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2 Objectives 
The possibility of quantification of multiple RAS peptides by a MS based method 
may provide drug-type specific RAS peptide profiles that could e.g. be useful for 
the assessment of uncontrolled hypertension under RAS inhibitor treatment. In 
combination with measured drug concentrations, RAS peptide profiles could serve 
as a tool to differentiate between true drug resistance and non-adherence and also 
to investigate the response to antihypertensive drug treatment. In a pilot study in 
healthy individuals, where the RAS peptides were investigated under normal 
conditions and after single dose administration of approved drugs that inhibit key 
enzymes of the RAS (renin, angiotensin-converting enzyme) or block Ang 1-8 at 
the receptor (angiotensin receptor antagonists), changes reflecting the mechanism 
of action of these drugs were evident within a few hours after administration of a 
single dose. 
The goals of this dissertation were therefore to investigate and characterize 
RAS peptide profiles in healthy normotensive subjects and later in different 
conditions in relation with high blood pressure. The work should contribute to a 
better understanding of RAS peptides and investigate their clinical usability as 
biomarkers of drug effect and or drug adherence. 
The following section presents non-published data from this dissertation 
project, starting with the first project, assessing RAS peptide concentrations after 
single and repeated oral administration of the renin inhibitor aliskiren, the ACE 
inhibitor enalapril, and the angiotensin receptor antagonist losartan in healthy 
normotensive subjects. In a second project, the potential of drug-specific profiles 
found in healthy normotensive subjects were assessed in patients with a new 
diagnosis of arterial hypertension before and after start of antihypertensive 
monotherapy. RAS peptide profiles were assessed after 4 weeks of consecutive 
oral treatment with intermediate and high doses of four drugs used as first line 
treatments, namely the ACE inhibitor perindopril, the angiotensin receptor 
antagonist olmesartan, the calcium channel antagonist amlodipine or the diuretic 
hydrochlorothiazide. Preliminary data confirming drug-specific changes observed 
in healthy normotensive subjects led to the third project where the RAS peptide 
profiles were investigated in patients referred to the hospital for the work-up of 
uncontrolled arterial hypertension. 
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3 Results 
3.1 RAS peptide profiles in healthy subjects 
Angiotensin peptide profiles in non-salt-depleted healthy subjects 
after single and multiple dose treatment with aliskiren, enalapril and 
losartan 
 
Andrea Stoller 1, Marko Poglitsch 2, Massimiliano Donzelli 1, Anne Taegtmeyer 1, Stephan 
Krähenbühl 1, Manuel Haschke 1 
 
 
1) Division of Clinical Pharmacology & Toxicology, University Hospital Basel and Department 
of Clinical Research, University of Basel, Switzerland 
2) Attoquant Diagnostics GmbH, Vienna, Austria 
 
 
Clinical Trials ID: NCT01771783 
 
 
Keywords: 
Renin-angiotensin system, angiotensin peptides, ACE inhibitor, angiotensin receptor 
antagonist, renin inhibitor, healthy subjects 
 
 
Unpublished 
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Abstract 
 
Background The renin-angiotensin system (RAS) plays an important role in blood pressure 
and fluid balance regulation. Important effectors of the RAS are small bioactive peptides like 
angiotensin II (Ang 1-8) or Ang 1-7. Frequently used cardiovascular drugs, such as renin or 
ACE inhibitors or angiotensin receptor antagonists act on key enzymes or receptors of the 
RAS, and are expected to cause drug-type specific changes of RAS peptide concentrations. 
The objective of this study was to assess RAS peptide concentrations after single and 
repeated oral administration of the renin inhibitor aliskiren, the ACE inhibitor enalapril, and 
the angiotensin receptor antagonist losartan in normotensive subjects. 
Methods In a single-center, open-label, randomized, 3-way crossover study 12 healthy, 
normotensive male subjects received once-daily doses of 10 mg enalapril, 50 mg losartan, or 
150 mg aliskiren in three sequential treatment periods. Concentrations of RAS inhibitors and 
RAS peptides were determined using a liquid chromatography-tandem mass spectrometry 
method before, and 2, 4, 8, and 24 hours after administration of a single dose and after 8 
days of repeated once-daily dosing. Circulating RAS peptide concentrations were determined 
from aliquots containing protease inhibitors and equilibrium angiotensin concentrations from 
standard lithium heparin aliquots. 
Results In untreated subjects, circulating RAS peptide concentrations were in the low 
picomolar range. Single dose treatment caused drug-specific changes of circulating 
angiotensin peptide profiles which directly reflect the mechanism of action of the different 
RAS inhibitors. The renin inhibitor aliskiren decreased downstream RAS peptide 
concentrations. The ACE inhibitor enalapril increased concentrations of the ACE substrates 
angiotensin I (Ang 1-10) and Ang 1-7. The angiotensin receptor antagonist losartan 
increased concentrations of Ang 1-10 and Ang 1-8. In RAS equilibrium analysis the 
drug-specific qualitative alterations of circulating RAS peptide profiles were preserved. In 
equilibrium profiles RAS peptide concentrations were higher and unmasked additional 
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drug-specific changes in Ang 2-10, Ang 2-8 and Ang 3-8 compared to circulating peptide 
profiles. 
Conclusion Circulating and equilibrium RAS peptide profiles show drug-specific changes 
which directly reflect the mechanism of action of the different RAS inhibitors after single and 
multiple dose treatment for one week. Equilibrium samples contain higher RAS peptide 
concentrations and show additional drug-specific changes in small downstream peptides 
compared to circulating RAS peptide profiles. The present data suggest that RAS equilibrium 
peptide profiles could be of value for the stratification and monitoring of patients under RAS 
inhibitor therapy. Their potential as possible biomarkers in such patients will have to be 
assessed in subsequent studies. 
 
 
Introduction 
 
The renin-angiotensin system (RAS) plays an important role in the regulation of blood 
pressure and is involved in vascular injury and repair responses.[1] Angiotensin II (Ang 1-8) 
is the main effector peptide of the classic RAS. It is formed by C-terminal cleavage of two 
amino acids from Angiotensin I (Ang 1-10), a reaction catalyzed by the di-carboxypeptidase 
angiotensin-I-converting enzyme (ACE). The classic effects of Ang 1-8, such as 
vasoconstriction, stimulation of aldosterone and antidiuretic hormone release, and increase 
of renal sodium and water reabsorption are mediated by binding of Ang 1-8 to the 
angiotensin II type 1 receptor (AT1). 
In 2000, a tissue specific human homologue of ACE, called angiotensin-I-converting enzyme 
2 (ACE2) was described.[2, 3] In contrast to ACE that removes a dipeptide, ACE2 only 
cleaves a single amino acid from the carboxy terminus of Ang 1-10 or Ang 1-8 to produce 
Ang 1-9 or Ang 1-7, respectively.[3] While for Ang 1-9 no specific receptor has been 
described yet, Ang 1-7 binds to MAS1, a G-protein coupled receptor.[4] This non-classic 
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ACE2 – Ang 1-7 – MAS1 axis is reported to mediate opposing effects to the classic RAS 
axis, such as vasodilation, vascular protection and anti-proliferation as well as 
anti-fibrinogenic, anti-thrombogenic and anti-arrythmogenic effects.[5-7] Ang 1-8 and Ang 1-7 
are further cleaved by amino- and/or carboxypeptidases to Ang III (Ang 2-8)[8], Ang IV 
(Ang 3-8)[9], Ang 2-7[10, 11] or Ang 3-7.[12] While Ang 2-8 has effects similar to Ang 1-8 
mediated by angiotensin receptors, Ang 3-8 is thought to have anti-inflammatory and 
anti-fibrotic effects by inhibiting the insulin-regulated membrane aminopeptidase (IRAP).[13, 
14] Possible cardiovascular or CNS effects of the smaller fragments Ang 2-7 and Ang 3-7 are 
less well documented.[10, 12]  
Reliable quantification of these small low abundance peptides is a technical challenge. The 
first quantifications of Ang 1-8 were performed with radioimmunoassays several decades 
ago.[15-17] The antibodies used were specific for the C-terminal sequence of Ang 1-8 and 
differentiated between Ang 1-10 and Ang 1-8 but cross-reacted with smaller angiotensin 
peptide fragments with identical C-terminal amino acid sequence as Ang 1-8.[18] Separation 
of the different angiotensin peptides using HPLC before performing the RIA improved the 
specificity of the method and allowed specific quantification of Ang 1-8 and other angiotensin 
metabolites.[19, 20] In recent years, several mass spectrometry based methods have been 
developed for the quantification of angiotensin peptides in human plasma, which introduced 
a high degree of specificity and the ability to control for sample preparation recovery by using 
stable isotope labeled peptides for internal standardization.[21-25]  
Addition of a protease inhibitor cocktail during sample collection stabilizes peptide levels and 
allows quantification of circulating angiotensin peptide concentrations. Alternatively, without 
specific sampling requirements, equilibrium concentrations of RAS peptides can be 
determined in heparin plasma or serum samples.[26] 
According to their different mechanisms of action, cardiovascular drugs such as renin or ACE 
inhibitors, or angiotensin receptor antagonists will cause characteristic concentration 
changes of Ang 1-10, Ang 1-8 and possibly also of smaller downstream RAS peptides. 
Simultaneous quantification of multiple RAS peptides may provide drug-type specific RAS 
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peptide profiles that could be useful for the assessment of patients under RAS inhibitor 
treatment. As a first step, we characterized circulating and equilibrium RAS peptide profiles 
after single and repeated doses of the renin inhibitor aliskiren, the ACE inhibitor enalapril and 
the angiotensin receptor antagonist losartan in healthy, normotensive subjects. 
 
 
Methods 
 
Clinical Study 
A single-center, randomized, open-label, 3-way crossover study 
(ClinicalTrials.gov ID: NCT01771783) was performed at the Phase I Research Unit, 
University Hospital Basel, Switzerland. The study was approved by the local Ethics 
Committee (Ethikkommission Basel) and the national regulatory authorities (Swiss Agency 
for Therapeutic Products, Swissmedic) and conducted in accordance with the principles of 
the Declaration of Helsinki. 
Healthy, normotensive male subjects were randomized to one of three treatment groups. In 
every treatment group, study subjects received eight oral doses of 10 mg enalapril, 50 mg 
losartan, and 150 mg aliskiren in a different sequence with a wash out period of at least 13 
days between the different treatment periods. One day before starting with the first treatment 
period, blood samples for the assessment of baseline peptide profiles were collected. On day 
1 and 8 of each treatment period the subjects were fasted for 10 h before until 4 h after 
administration of study medication. Standardized meals were served 4 h, 6 h and 10 h after 
study drug intake. 
Venous blood samples were obtained from an indwelling venous catheter placed in the 
non-dominant forearm before and 1, 2, 4, 8, 12 and 24 h after drug administration on day 1 
and on day 8 of each treatment period. For the analysis of circulating RAS peptide 
concentrations, blood was collected into tubes containing broad spectrum inhibitors against 
metalloproteases (ethylenediaminetetraacetic acid [EDTA], 1,10-phenanthroline), aspartic 
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proteases (pepstatin A), cysteine proteases (p-hydroxymercuribenzoic acid), serine 
proteases (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride [AEBSF]) and specific 
inhibitors for renin and aminopeptidases A and N to a final concentration of 5% v/v 
(Attoquant Diagnostics, Vienna, Austria). 
For the analysis of ex vivo equilibrium RAS peptide concentrations, blood was collected into 
standard lithium heparin tubes. Equilibrium angiotensin peptide levels were measured 
following 30 min of equilibration of conditioned Li-Heparin plasma at 37°C and subsequent 
stabilization of equilibrium peptide levels. For the analysis of drug and renin concentrations 
blood was collected into EDTA tubes. All tubes were centrifuged within 30 min at 1500 g for 
10 min at 4 °C and plasma was stored at -80°C until analysis. 
Blood pressure and heart rate were recorded from the subjects in supine position for at least 
10 min using an automatic oscillometric device. Measurements were done on the dominant 
arm at the time points of blood sample collection. At each time point, blood pressure and 
heart rate were measured three consecutive times with an interval of at least one minute 
between measurements and the average of the three readings was recorded. If two blood 
pressure readings differed by more than 5 mmHg, an additional measurement was done and 
the outlier was excluded for the calculation of the average. 
No concomitant medication was allowed, except for the treatment of AEs. Consumption of 
alcoholic beverages was not allowed. All subjects were requested to follow a diet 
recommendation to prevent dietary salt excess for 72 h prior to each treatment period until 
after the collection of the last blood sample of each treatment period. Urine sodium excretion 
was determined in 24 h urine samples collected on day 1 and day 8 of each treatment 
period. 
 
Study Drugs 
Enalapril (Reniten®, MSD Merck Sharp & Dohme AG), losartan (Cosaar®, MSD Merck 
Sharp & Dohme AG), and aliskiren (Rasilez®, Novartis Pharma Schweiz AG) were 
purchased through the hospital pharmacy of the University Hospital Basel. 
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Materials and Reagents 
Losartan, losartan-d4, losartan carboxylic acid (E-3174), enalaprilat, enalaprilat-d5, aliskiren, 
and aliskiren-d6 were purchased from Toronto Research Chemicals (Toronto, ON, Canada). 
Formic acid, high-performance liquid chromatography (HPLC)-grade methanol and water 
were purchased from Merck KGaA (Darmstadt, Germany). 
Stable isotope labeled internal standards for angiotensin metabolites and MS grade formic 
acid were purchased from Sigma-Aldrich (Vienna, Austria). LC-MS-grade water, methanol 
and acetonitrile were purchased from Fisher Scientific (Vienna, Austria). The protease 
inhibitor cocktail containing EDTA, Pepstatin A, p-hydroxymercuribenzoic acid, AEBSF and 
specific inhibitors for renin and aminopeptidases A and N was provided by Attoquant 
Diagnostics (Vienna, Austria). 
 
Measurement of Drug Concentrations 
Concentrations of losartan, E-3174, enalaprilat, and alsikiren in plasma were determined by 
reversed-phase HPLC with tandem mass spectrometry (HPLC–MS/MS). Briefly, 50 μL 
aliquots of plasma were mixed with 150 μL of an internal standard solution containing 
deuterated analogues of the study drugs at a concentration of 10 ng/mL, vortex mixed for 30 
seconds and centrifuged (3,220g for 30 min at 10°C). Ten microlitres of deproteinized 
supernatant were injected directly into the HPLC–MS/MS system. Chromatographic 
separation was done on a Shimadzu HPLC system (Shimadzu AG, Reinach, Switzerland) 
coupled to a triple quadrupole tandem mass spectrometer (API4000, Applied Biosystems, 
Rotkreuz, Switzerland) operating in electrospray-ionization positive-ion mode. An 
Atlantis T3 column (50 x 2.1 mm, Waters, Baden-Dättwil, Switzerland) was used for the 
separation of the analytes. The total run time was 2.3 min. Samples were quantified using 
peak area ratios. The assays were linear in the concentration ranges 1-250 ng/mL for 
losartan, E-3174, and alsikiren, and 1-100 ng/mL for enalaprilat. Concentrations were 
calculated by interpolation from a calibration curve. Quality control samples were analyzed 
throughout the sample analysis. 
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Quantification of RAS Peptide Concentrations 
Following 30 min of equilibration of conditioned Li-heparin plasma at 37°C, stabilized 
samples for quantification of angiotensin metabolite concentrations were spiked with stable 
isotope-labeled internal standards for each angiotensin metabolite (Ang 1-10, Ang 1-9, 
Ang 1-8, Ang 1-7, Ang 1-5, Ang 2-10, Ang 2-8, Ang 2-7, Ang 3-8, and Ang 3-7) at a 
concentration of 100 pg/ml. Following C18-based solid-phase-extraction, samples were 
subjected to LC-MS/MS analysis using a reversed-phase analytical column (Acquity UPLC® 
C18, Waters) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer 
(Waters) in MRM mode. Internal standards were used to correct for peptide recovery of the 
sample preparation procedure for each angiotensin metabolite in each individual sample. 
Angiotensin metabolite concentrations were calculated considering the corresponding 
response factors determined in appropriate calibration curves in original sample matrix, on 
condition that integrated signals exceeded a signal-to-noise ratio of 10. Lower limits of 
quantification (LLOQ) for the different angiotensin peptides were between 1 and 5 pg/ml 
(Supplementary Table 2). 
 
Pharmacokinetic Analysis 
Plasma concentration data were analyzed using noncompartmental methods. Peak plasma 
concentrations (Cmax) and time to reach Cmax (tmax) were directly obtained from observed 
concentration-time data. The terminal elimination rate constant (λz) was determined by 
log-linear regression using at least three data points. The area under the concentration–time 
curve (AUC) from zero to 24 h after dosing (AUC0-24) was estimated using the linear 
trapezoidal method. The terminal elimination half-life was calculated using λz. Calculations 
were done using the PK Solver add-in (version 2.0) for Microsoft Excel.[27] 
 
Statistical analysis 
Changes of systolic and diastolic blood pressure and heart rate were evaluated by 
comparing area under the effect-time curves from time zero to 8 hours (AUEC0-8h). Statistical 
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analysis was performed using GraphPad Prism, version 5.03 (GraphPad Sofware, Inc., 
USA). Normal distribution of the data was assessed using Bartlett’s test. Parameters with a 
normal distribution were tested using one-way analysis of variance (ANOVA). Post-hoc 
analysis of significant overall results was done with Dunnett’s test for multiple comparisons. 
Non-normally distributed parameters were analyzed by the non-parametric Friedman test. 
For post-hoc analysis of significant overall results Dunn’s test for multiple comparisons was 
used. 
 
 
Results 
 
Clinical study 
Twelve healthy, non-smoking male volunteers (median age 29 years, range 22 – 42 years, 
median body mass index 22.6 kg/m2, range 18.4 – 26.8 kg/m2) completed the study 
according to the protocol. Ten study subjects were of Caucasian ethnicity, one subject was of 
Indian and another subject of South-Amercian descent. They all had no history of relevant 
disease or drug abuse, normal findings on physical examination, normal blood pressure 
(median systolic blood pressure 129 mmHg, range 118-139 mmHg, median diastolic blood 
pressure 76 mmHg, range 68-88 mmHg), normal screening laboratory tests (including 
screening for drugs of abuse), and normal electrocardiograms. The mean (±sd) urinary 
sodium excretion was 173 (±60) mmol/24 hours (corresponding to 10.1±3.5 grams of dietary 
sodium chloride) without any statistical difference between the baseline assessment and the 
different treatment periods. 
Plasma concentration-time profiles of aliskiren, enalaprilat and losartan carboxylic acid after 
single and repeated once daily dosing are shown in Figure 1 and pharmacokinetic 
parameters are listed in Supplementary Table 1. Drug exposure after repeated dosing was 
not significantly different compared to single dose administration and in line with published 
values.[28-30] 
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A) 
 
Figure 1. Mean (sd) plasma 
concentration–time profiles of 
aliskiren (A), enalaprilat (B), 
and losartan carboxylic acid 
(E3174, C) after single and 
repeated once-daily oral 
administration of aliskiren 
150 mg, enalapril 10 mg, and 
losartan 50 mg to healthy 
subjects (n = 12). 
B) 
  
C) 
 
 
 
Mean systolic blood pressure without treatment was 118 mmHg (range 103-145 mmHg) and 
mean heart rate was 58 beats per minute (range 43-77 bpm) without any significant changes 
during the 8 hour assessment period. The effects of single and multiple dose treatment with 
aliskiren, enalapril or losartan on blood pressure and heart rate are shown in Table 1. The 
largest effect was observed between 2 and 4 hours after single dose enalapril with a maximal 
decrease of systolic blood pressure of 7 mmHg and a maximal decrease of heart rate of 
3 bpm. Single and multiple dose treatment with aliskiren or losartan had smaller effects on 
blood pressure and heart rate compared to enalapril. 
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Angiotensin peptide concentrations in untreated subjects 
Without treatment, concentrations of circulating RAS peptides in healthy, normotensive, 
non-salt-depleted subjects were low. During the 8 hour baseline assessment, median 
concentrations of circulating Ang 1-10 and Ang 1-8 were between 12-16 pg/ml 
(range 6-100 pg/ml) and 9-12 pg/ml (range 1-68 pg/ml), respectively. Concentrations of 
Ang 1-9 were below the lower limit of quantification (LLOQ) in all subjects, and circulating 
concentrations of the remaining peptides (Ang 1-7, Ang 1-5, Ang 2-10, Ang 2-8, Ang 2-7, 
Ang 3-8, Ang 3-7) could only be quantified in some of the subjects (Table 2). There was no 
time-dependent change of quantifiable peptide concentrations during the 8 hour observation 
period. A representative bubble plot scheme of circulating RAS peptide concentrations in 
untreated healthy subjcets including enzymes involved in formation or degradation of the 
measured RAS peptides is shown in Figure 2. 
In RAS equilibrium analysis, concentrations of Ang 1-8 were approx. five-fold higher (median 
41-70 pg/ml) compared to circulating Ang 1-8 concentrations, whereas concentrations of all 
the other peptides in the equilibrium samples were comparable to circulating peptide 
concentrations (Table 3). Data of one subject had to be excluded due to pathologically 
increased renin concentrations. 
 
Figure 2. A representative bubble plot scheme of 
circulating angiotensin concentrations in untreated, 
normotensive, healthy subjects (n=12). 
The diameter of the bubble corresponds to the median 
concentration (pg/ml), the numeric value of the median 
concentration is given below the peptide designation according to 
the number of amino acids in parenthesis. The arrows designate 
known degradation pathways with the responsible enzymes. 
ACE, angiotensin converting enzyme; AP, aminopeptidase A; 
DAP, dipeptidyl aminopeptidase; NEP, neutral endopeptidase. 
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Table 1. Maximum changes of blood pressure and heart rate without treatment (baseline) and after single and repeated dose treatment with 
aliskiren, enalapril and losartan.  
 
 Baseline Aliskiren Enalapril Losartan 
  Day 1 Day 8 Day 1 Day 8 Day 1 Day 8 
Systolic blood pressure        
Maximum change (mmHg) 1 
(+13 / -16) 
1 
(15 – -20) 
-4 
(14 – -17) 
-7 
(10 – -20) 
-3 
(10 – -22) 
-2 
(18 – -24) 
0 
(15 – -13) 
AUEC (mmHg x h) 5 
(57 – -93) 
-8 
(60 – -116) 
-11 
(46 – -136) 
-48 
(35 – -109) 
-27 
(46 – -135) 
-11 
(32 – -157) 
-33 
(58 – -159) 
        
Diastolic blood pressure 
       
Maximum change (mmHg) -1 
(9 – -12) 
-2 
(14 – -16) 
-4 
(11 – -14) 
-9 
(8 – -17) 
-6 
(4 – -18) 
-4 
(7 – -18) 
-5 
(6 – -15) 
AUEC (mmHg x h) -6 
(38 – -69) 
-11 
(34 – -99) 
-27 
(33 – -144) 
-64 
(29 – -94) 
-42 
(-8 – -106) 
-21 
(20 – -122) 
-43 
(21 – -129) 
        
Heart rate 
       
Maximum change (beats/min) 0 
(24 – -14) 
1 
(14 – -20) 
-2 
(10 – -12) 
-3 
(12 – -15) 
-3 
(12 – -14) 
1 
(13 – -7) 
-1 
(14 – -20) 
AUEC (beats/min x h) 3 
(138 – -76) 
5 
(39 – -126) 
-23 
(26 – -110) 
-4 
(43 – -88) 
-7 
(122 – -84) 
1 
(70 – -29) 
18 
(85 – -57) 
 
Data are given as median (range). AUEC, area under effect curve from 0 to 8 hours. 
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Table 2.  Circulating angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or losartan. 
 
Baseline 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
0 
<7 
(<5 – 87) 
6) 
<4 
 
9 
(<1 – 68) 
11) 
<3 
(<3 – 13) 
2) 
<1 
(<1 – 3) 
3)
 
<3 
(<3 – 2) 
1) 
<2 
 
<4 
 
2 
(<1 – 6) 
7)
 
<1 
(<1 – 1) 
1)
 
2 
14 
(<5 – 45) 
8) 
<4 10 
(2 – 38) 
 
<3 
 
<1 
(<1 – 3) 
1)
 
<3 
(<3 – 8) 
2) 
<2 
 
<4 
 
2 
(<1 – 5) 
7)
 
<1 
 
4 
<8 
(<5 – 100) 
6) 
<4 12 
(<1 – 40) 
10) 
<3 
(<3 – 8) 
3) 
<1 
(<1 – 3) 
3)
 
<3 
(<3 – 4) 
2) 
<2 
 
<4 
 
<2 
(<1 – 5) 
6)
 
<1 
(<1 – 2) 
2)
 
8 
<5 
(<5 – 28) 
5) 
<4 9 
(2 – 32) 
 
<3 
(<3 – 7) 
2) 
<1 
(<1 – 3) 
1)
 
<3 
(<3 – 8) 
2) 
<2 
 
<4 
 
1 
(<1 – 4) 
9)
 
<1 
 
 
Aliskiren 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
13 
(<5 – 105)
 8)
 
<4 8 
(2 – 48)  
<3 
(<3 – 3)
 2)
 
<1 
(<1 – 2)
 3)
 
<3 
(<3 – 5)
 2)
 
<2 <4 
(<4 – 6)
 1)
 
2 
(<1 – 4)
 8)
 
<1 
(<1 – 1) 
1)
 
2 
<5 
(<5 – 5)
 1)
 
<4 4 
(<1 – 20) 
11)
 
<3 
(<3 – 9)
 3)
 
<1 
(<1 – 2)
 2)
 
<3 
 
<2 <4 2 
(<1 – 2)
 7)
 
<1 
(<1 – 2) 
1)
 
4 
<5 
 
<4 6 
(<1 – 29) 
9)
 
<3 
(<3 – 4)
 1)
 
<1 
(<1 – 3)
 2)
 
<3 
(<3 – 3)
 3)
 
<2 <4 <1 
(<1 – 3)
 4)
 
<1 
(<1 – 4) 
1)
 
8 
<5 
(<5 – 24)
 2)
 
<4 3 
(<1 – 24) 
11)
 
<3 
(<3 – 8)
 2)
 
<1 
(<1 – 2)
 1)
 
<3 
  
<2 <4 <1 
(<1 – 3)
 5)
 
<1 
(<1 – 1) 
1)
 
24 
17 
(<5 – 39)
 8)
 
<4 9 
(3 – 29) 
<3 
  
<1 
(<1 – 3)
 4)
 
<3 
(<3 – 7)
 3)
 
<2 <4 1 
 (<1 – 2)
 7)
 
<1 
168 
12 
(<5 – 17)
 6)
 
<4 8 
(<1 – 29) 
11)
 
<3 
(<3 – 15)
 2)
 
<1 
(<1 – 2)
 2)
 
<3 
  
<2 <4 <1 
 (<1 – 7)
 5)
 
<1 
170 
<5 
 
<4 6 
(2 – 15)  
<3 
 
<1 
(<1 – 3)
 3)
 
<3 
(<3 – 6)
 3)
 
<2 <4 <1 
 (<1 – 4)
 6)
 
<1 
(<1 – 1) 
1)
 
172 
<5 
(<5 – 25)
 2)
 
<4 4 
(<1 – 17) 
11)
 
<3 
(<3 – 4)
 1)
 
<1 
(<1 – 4)
 2)
 
<3 
(<3 – 3)
 3)
 
<2 <4 
(<4 – 9)
 1)
 
<1 
 (<1 – 3)
 6)
 
<1 
176 
<5 
(<5 – 15)
 5)
 
<4 7 
(<1 – 22) 
11)
 
<3 
(<3 – 8)
 2)
 
<1 
(<1 – 2)
 4)
 
<3 
(<3 – 4)
 1)
 
<2 <4 
(<4 – 8)
 2)
 
<1 
 (<1 – 4)
 6)
 
<1 
192 
10 
(<5 – 18)
 9)
 
<4 7 
(1 – 29)  
<3 
(<3 – 3)
 1)
 
<1 
(<1 – 4)
 2)
 
<3 
(<3 – 6)
 2)
 
<2 <4 
 
1 
 (<1 – 4)
 8)
 
<1 
 
Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
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Table 2 cont.  Circulating angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or losartan. 
 
Enalapril 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
14 
(<5 – 64)
 7)
 
<4 7 
(<1 – 38)
 11)
 
<3 
 
<1 
(<1 – 2)
 2)
 
<3 
(<3 – 12)
 4)
 
<2 <4 
(<4 – 6)
 1)
 
<1 
(<1 – 4)
 6)
 
<1 
 
2 
35 
(<5 – 312)
 11)
 
<4 4 
(<1 – 20)
 11)
 
<3 
(<3 – 10)
 4)
 
<1 
(<1 – 3)
 2)
 
<3 
(<3 – 14)
 5)
 
<2 <4 2 
(<1 – 3)
 7)
 
<1 
(<1 – 1) 
1)
 
4 
82 
(<5 – 299)
 11)
 
<4 3 
(1 – 22)
 
 
7 
(<3 – 16)
 9)
 
<1 
(<1 – 4)
 2)
 
4 
(<3 – 18)
 8)
 
<2 <4 <1 
(<1 – 2)
 5)
 
<1 
(<1 – 3)
 3)
 
8 
88 
(8 – 287)
 
 
<4 
(<4 – 5)
 1)
 
4 
(<1 – 17)
 10)
 
7 
(<3 – 13)
 7)
 
<1 
(<1 – 5)
 2)
 
<3 
(<3 – 7)
 6)
 
<2 <4 
  
<1 
(<1 – 5)
 5)
 
<1 
(<1 – 2) 
1)
 
24 
29 
(11 – 164)
 
 
<4 
(<4 – 7)
 1)
 
7 
(<1 – 20)
 11)
 
<3 
(<3 – 4)
 2)
 
<1 
(<1 – 5)
 3)
 
<3 
(<3 – 12) 
3)
 
<2 <4 2 
(<1 – 2)
 7)
 
<1 
(<1 – 4) 
1)
 
168 
46 
(18 – 194)
 
 
<4 
 
10 
(<1 – 15)
 11)
 
<3 
(<3 – 9)
 2)
 
<1 
(<1 – 4)
 5)
 
<3 
(<3 – 19)
 6)
 
<2 <4 2 
(<1 – 3)
 7)
 
<1 
(<1 – 2)
 2)
 
170 
219 
(9 – 1002)
 
 
<4 4 
(<1 – 17)
 11)
 
10 
(<3 – 43)
 9)
 
<1 
(<1 – 4)
 2)
 
5 
(<3 – 14)
 9)
 
<2 
 
<4 
(<4 – 6)
 3)
 
<1 
(<1 – 3)
 6)
 
<1 
(<1 – 5)
 4)
 
172 
192 
(36 –1711)
 
 
<4 5 
(<1 – 31)
 11)
 
12 
(<3 – 97)
 9)
 
<1 
(<1 – 2)
 3)
 
5 
(<3 – 11)
 8)
 
<2 
  
<4 
(<4 – 6)
 1)
 
<1 
(<1 – 3)
 5)
 
<1 
(<1 – 8)
 5)
 
176 
179 
(14 – 603)
 
 
<4 6 
(<1 – 33)
 11)
 
11 
(<3 – 20)
 9)
 
<1 
(<1 – 3)
 1)
 
<3 
(<3 – 8)
 5)
 
<2 <4 
(<4 – 5)
 2)
 
2 
(<1 – 3)
 7)
 
<1 
(<1 – 6)
 2)
 
192 
41 
(20 – 187)
 
 
<4 11 
(6 – 22)
 
 
<3 
 
<1 
 
<3 
(<3 – 6)
 5)
 
<2 <4 
(<4 – 4)
 1)
 
<1 
(<1 – 4)
 5)
 
<1 
(<1 – 2)
 2)
 
 
Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
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Table 2 cont.  Circulating angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or losartan. 
 
Losartan 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
13 
(<5 – 39)
 7)
 
<4 7 
(1 – 45)
 
 
<3 
(<3 – 4)
 1)
 
<1 
(<1 – 4)
 2)
 
<3 
(<3 – 11)
 3)
 
<2 <4 
(<4 – 5)
 1)
 
<1 
(<1 – 3)
 6)
 
<1 
(<1 – 3)
 2)
 
2 
24 
(<5 – 171)
 8)
 
<4 14 
(4 – 89)
 
 
<3 
(<3 – 9)
 3)
 
<1 
(<1 – 2)
 4)
 
<3 
(<3 – 6)
 4)
 
<2 <4 2 
(<1 – 4)
 8)
 
<1 
(<1 – 2) 
1)
 
4 
71 
(<5 – 169)
 8)
 
<4 36 
(3 – 187)
 
 
<3 
(<3 – 5)
 1)
 
<1 
(<1 – 4)
 5)
 
<3 
(<3 – 4)
 4)
 
<2 <4 2 
(<1 – 6)
 8)
 
<1 
(<1 – 1)
 2)
 
8 
38 
(<5 – 346)
 10)
 
<4 23 
(3 – 217)
 
 
<3 
(<3 – 9)
 2)
 
2 
(<1 – 6)
 7)
 
<3 
(<3 – 9)
 3)
 
<2 <4 2 
(<1 – 8)
 7)
 
<1 
 
24 
32 
(6 – 87)
 
 
<4 18 
(8 – 45)
 
 
BLQ 
<1 
(<1 – 2)
 4)
 
<3 
(<3 – 6)
 2)
 
<2 <4 <1 
(<1 – 3)
 6)
 
<1 
(<1 – 2) 
1)
 
168 
31 
(8 – 122)
 
 
<4 22 
(9 – 144)
 
 
<3 
(<3 – 10)
 2)
 
<1 
(<1 – 4)
 5)
 
<3 
(<3 – 3)
 3)
 
<2 <4 2 
(<1 – 5)
 8)
 
<1 
170 
39 
(15 – 251)
 
 
<4 26 
(11 – 149)
 
 
<3 
(<3 – 7)
 3)
 
<1 
(<1 – 4)
 6)
 
<3 
(<3 – 4)
 1)
 
<2 <4 
 
3 
(<1 – 6)
 8)
 
<1 
172 
73 
(22 – 305)
 
 
<4 45 
(20 – 231)
 
 
<3 
(<3 – 13)
 3)
 
2 
(<1 – 9)
 10)
 
<3 
  
<2 
(<2 – 2) 
1)
 
<4 2 
(<1 – 7)
 8)
 
<1 
176 
78 
(16 – 241)
 
 
<4 64 
(19 – 203)
 
 
<3 
(<3 – 4)
 2)
 
2 
(<1 – 7)
 10)
 
<3 
(<3 – 4)
 2)
 
<2 
(<2 – 2) 
1)
 
<4 3 
(<1 – 7)
 10)
 
<1 
(<1 – 2)
 2)
 
192 
46 
(16 – 115)
 
 
<4 22 
(12 – 59)
 
 
<3 
(<3 – 5)
 3)
 
2 
(<1 – 3)
 7)
 
<3 
(<3 – 5)
 1)
 
<2 
 
<4 2 
(<1 – 4)
 9)
 
<1 
 
 
Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
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Table 3.  Equilibrium angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or losartan. 
 
Baseline 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
0 
16 
(<5 – 209) 
10)
 
<4 
(<4 – 8) 
2)
 
66 
(18 – 647)  
<3 
(<3 – 15) 
3)
 
2 
(<1 – 7) 
8)
 
<3 
(<3 – 5) 
4)
 
<2 
(<2 – 16) 
6)
 
<5 
 
<1 
(<1 – 25) 
6)
 
<1 
(<1 – 3) 
6)
 
2 
16 
(<5 – 218) 
9)
 
<4 
(<4 – 12) 
2)
 
70 
(11 – 561)  
<3 
(<3 – 17) 
4)
 
1 
(<1 – 4) 
9)
 
<3 
(<3 – 5) 
5)
 
<2 
(<2 – 14) 
6)
 
<5 
 
2 
(<1 – 14) 
9)
 
<1 
(<1 – 2) 
5)
 
4 
16 
(<5 – 241) 
10)
 
<4 
45 
(<2 – 207) 
11)
 
<3 
(<3 – 4) 
2)
 
<1 
(<1 – 8) 
3)
 
<3 
(<3 – 8) 
4)
 
<2 
(<2 – 5) 
3)
 
<5 
2 
(<1 – 3) 
8)
 
<1 
(<1 – 3) 
4)
 
8 
17 
(<5 – 148) 
11)
 
<4 
(<4 – 5) 
1)
 
41 
(3 – 526)  
<3 
(<3 – 12) 
4)
 
2 
(<1 – 11) 
10)
 
<3 
(<3 – 8) 
5)
 
<2 
(<2 – 13) 
5)
 
<5 
(<5 – 6) 
2)
 
2 
(<1 – 14) 
8)
 
<1 
(<1 – 1) 
4)
 
 
Aliskiren 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
19 
 (<5 – 97)
 11)
 
<4 
(<4 – 5)
 2)
 
89 
(6 – 400)
 
 
<3 
(<3 – 6)
 5)
 
2 
(<1 – 4)
 9)
 
<3 
(<3 – 3)
 5)
 
<2 
(<2 – 13)
 4)
 
<5 
(<5 – 5)
 4)
 
3 
(<1 – 16)
 8)
 
<1 
(<1 – 3)
 4)
 
2 
<5  
(<5 – 29)
 2)
 
<4 
(<4 – 9)
 3)
 
11 
(<2 – 80)
 11)
 
<3 
(<3 – 9)
 5)
 
<1 
(<1 – 2)
 5)
 
<3 
(<3 – 17)
 5)
 
<2 
(<2 – 5)
 1)
 
<5 
(<5 – 5)
 2)
 
<1 
(<1 – 3)
 4)
 
<1 
(<1 – 2)
 6)
 
4 
<5  
 (<5 – 9)
 2)
 
<4 
(<4 – 11)
 2)
 
8  
(<2 – 93)
 11)
 
<3 
(<3 – 4)
 2)
 
<1 
(<1 – 2)
 6)
 
<3 
(<3 – 11)
 5)
 
<2 
(<2 – 9)
 1)
 
<5 
(<5 – 6)
 2)
 
<1 
(<1 – 4)
 3)
 
<1 
(<1 – 2)
 3)
 
8 
<5 
(<5 – 50)
 6)
 
<4 
(<4 – 10)
 2)
 
33  
(<2 – 188)
 11)
 
<3 
(<3 – 10)
 3)
 
<1 
(<1 – 3)
 5)
 
<3 
(<3 – 10)
 4)
 
<2 
(<2 – 8)
 5)
 
<5 
(<5 – 5) 
1)
 
1 
(<1 – 8)
 7)
 
<1 
(<1 – 2)
 4)
 
24 
9 
(<5 – 54)
 10)
 
<4 
(<4 – 10)
 3)
 
64 
(26 – 264)
 
 
<3 
(<3 – 8)
 4)
 
2 
(<1 – 3)
 8)
 
<3 
(<3 – 13)
 5)
 
<2 
(<2 – 6)
 5)
 
<5 
 
2 
(<1 – 8)
 9)
 
<1 
(<1 – 2)
 3)
 
168 
16 
(<5 – 38)
 10)
 
<4 
(<4 – 4) 
1)
 
48 
(6 – 117)
 
 
<3 
(<3 – 14)
 3)
 
2 
(<1 – 7)
 7)
 
<3 
(<3 – 7)
 5)
 
<2 
(<2 – 5)
 3)
 
<5 
(<5 – 5)
 2)
 
2 
(<1 – 4)
 10)
 
<1 
(<1 – 2)
 3)
 
170 
9 
(<5 – 26)
 7)
 
<4 
(<4 – 7)
 2)
 
22 
(5 – 63)
 
 
<3 
(<3 – 13)
 4)
 
<1 
(<1 – 3)
 4)
 
<3 
(<3 – 11)
 5)
 
<2 
(<2 – 12)
 4)
 
<5 
(<5 – 5)
 2)
 
<1 
(<1 – 2)
 6)
 
<1 
(<1 – 2)
 5)
 
172 
<5 
(<5 – 17)
 5)
 
<4 
(<4 – 5)
 2)
 
21 
(5 – 51)
 
 
<3 
(<3 – 12)
 3)
 
<1 
(<1 – 2)
 4)
 
<3 
(<3 – 13)
 4)
 
<2 
(<2 – 5)
 4)
 
<5 
<1 
(<1 – 3)
 5)
 
<1 
(<0 – 4)
 4)
 
176 
15 
(<5 – 41)
 7)
 
<4 
(<4 – 8)
 3)
 
33 
(9 – 106)
 
 
<3 
(<3 – 9)
 4)
 
1 
(<1 – 3)
 7)
 
7 
(<3 – 13)
 8)
 
<2 
(<2 – 9)
 3)
 
<5 
(<5 – 5)
 2)
 
<1 
(<1 – 9)
 5)
 
<1 
(<1 – 2)
 3)
 
192 
19 
(<5 – 52)
 10)
 
<4 
 
56 
(10 – 186)
 
 
<3 
(<3 – 31)
 4)
 
2 
(<1 – 4)
 7)
 
<3 
(<3 – 17)
 5)
 
<2 
(<2 – 6)
 4)
 
<5 
(<5 – 5)
 3)
 
2 
(<1 – 4)
 7)
 
<1 
(<1 – 2)
 3)
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Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
Table 3 cont. Equilibrium angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or 
losartan. 
 
Enalapril 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
16 
(<5 – 49)
 11)
 
<4 
(<4 – 7)
 2)
 
55 
(5 – 259)
 
 
<5 
(<3 – 6)
 6)
 
2 
(<1 – 4)
 8)
 
<3 
(<3 – 9)
 5)
 
<2 
(<2 – 8)
 6)
 
<5 
(<5 – 5)
 3)
 
3 
(<1 – 6)
 8)
 
<1 
(<1 – 2)
 2)
 
2 
177 
(33 – 1131)
 
 
<4 
(<4 – 4) 
1)
 
10 
(2 – 96)
 
 
<6 
(<3 – 43)
 6)
 
<1 
(<1 – 1)
 6)
 
14 
(<3 – 133)
 9)
 
<2 
(<2 – 5)
 2)
 
<5 
 
<1 
(<1 – 5)
 3)
 
<1 
(<1 – 6)
 6)
 
4 
424 
(23 – 1826)
 
 
<4 
(<4 – 5)
 2)
 
16 
(<2 – 138)
 11)
 
27 
(<3 – 58)
 9)
 
<1 
(<1 – 4)
 6)
 
27 
(<3 – 106)
 10)
 
<2 
(<2 – 4)
 5)
 
<5 
(<5 – 8)
 4)
 
<1 
(<1 – 5)
 2)
 
1 
(<1 – 3)
 8)
 
8 
624 
(41 – 3001)
 
 
<4 
(<4 – 3)
 2)
 
16 
(3 – 219)
 
 
27 
(<3 – 60)
 10)
 
<1 
(<1 – 4)
 6)
 
36 
(<3 – 131)
 11)
 
<2 
(<2 – 9)
 2)
 
<5 
(<5 – 6)
 1)
 
<1 
(<1 – 9)
 6)
 
1 
(<1 – 3)
 7)
 
24 
164 
(25 – 339)
 
 
<4 
(<4 – 7) 
1)
 
62 
(16 – 260)
 
 
6 
(<3 – 13)
 7)
 
2 
(<1 – 4)
 9)
 
10 
(<3 – 20)
 8)
 
<3 
(<2 – 7)
 6)
 
<5 
 
2 
(<1 – 8)
 10)
 
2 
(<1 – 3)
 4)
 
168 
260 
(64 – 1545)
 
 
<4 
 
80 
(23 – 190)
 
 
9 
(<3 – 74)
 10)
 
2 
(<1 – 5)
 9)
 
12 
(3 – 87)
 
 
4 
(<2 – 6)
 7)
 
<5 
(<5 – 5)
 3)
 
3 
(<1 – 7)
 10)
 
1 
(<1 – 3)
 6)
 
170 
960 
(116 – 3229)
 
 
<4 
(<4 – 22)
 3)
 
38 
(8 – 135)
 
 
38 
(<3 – 134)
 10)
 
1 
(<1 – 5)
 7)
 
88 
(9 – 126)
 
 
5 
(<2 – 6)
 4)
 
<5 
 
2 
(<1 – 4)
 8)
 
2 
(<1 – 7)
 7)
 
172 
916 
(267 – 4288)
 
 
<4 
(<4 – 10)
 3)
 
16 
(7 – 112)
 
 
47 
(<3 – 107)
 11)
 
1 
(<1 – 4)
 8)
 
75 
(<3 – 176)
 11)
 
<2 
(<2 – 7)
 2)
 
<5 
(<5 – 6)
 4)
 
<1 
(<1 – 5)
 5)
 
2 
(<1 – 8)
 8)
 
176 
979 
(102 – 4502)
 
 
<4 
(<4 – 5)
 2)
 
51 
(2 – 303)
 
 
50 
(<3 – 153)
 10)
 
<1 
(<1 – 3)
 5)
 
62 
(9 – 248)
 
 
<2 
(<2 – 10)
 4)
 
<5 
(<5 – 7)
 4)
 
2  
(<1 – 13)
 7)
 
2 
(<1 – 8)
 9)
 
192 
158 
(112 – 807)
 
 
<4 
123 
(37 – 361)
 
 
13 
(<3 – 46)
 8)
 
2 
(<1 – 6)
 11)
 
12 
(<3 – 31)
 11)
 
6 
(<2 – 18)
 8)
 
<5 
 
4 
(<1 – 12)
 11)
 
2 
(<1 – 4)
 5)
 
 
Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
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Table 3 cont. Equilibrium angiotensin concentrations (pg/ml) before (baseline) and after single and multiple doses of aliskiren, enalapril or 
losartan. 
 
Losartan 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Predose 
14 
(<5 – 80)
 11)
 
<4 
 
50 
(24 – 371)
 
 
<3 
(<3 – 8)
 6)
 
1 
(<1 – 5)
 9)
 
<3 
(<3 – 9)
 5)
 
<2 
(<2 – 10)
 5)
 
<5 
2 
(<1 – 11)
 9)
 
<1 
(<1 – 2)
 4)
 
2 
33 
(6 – 184)
 
 
<4 
(<4 – 7)
 2)
 
151 
(43 – 997)
 
 
<3 
(<3 – 7)
 4)
 
2 
(<1 – 15)
 7)
 
<3 
(<3 – 12)
 4)
 
6 
(<2 – 30)
 8)
 
<5 
(<5 – 5)
 3)
 
4 
(<1 – 35)
 9)
 
<1 
(<1 – 2)
 2)
 
4 
108 
(<5 – 357)
 11)
 
<4 
 
283 
(42 – 2084)
 
 
<3 
(<3 – 19)
 5)
 
3 
(<1 – 38)
 11)
 
6 
(<3 – 15)
 8)
 
9 
(<2 – 71)
 9)
 
<5 
(<5 – 6)
 2)
 
7 
(<1 – 73)
 11)
 
<1 
(<1 – 1)
 3)
 
8 
111 
(13 – 841)
 
 
<4 
(<4 – 4)
 3)
 
261 
(79 – 2941)
 
 
6 
(<3 – 23)
 7)
 
4 
(<1 – 38)
 11)
 
6 
(<3 – 13)
 9)
 
7  
(<2 – 110)
 11)
 
<5 
(<5 – 5)
 2)
 
7 
(2 – 114)
 
 
<1 
(<1 – 1)
 5)
 
24 
73 
(13 – 208)
 
 
<4 
(<4 – 5)
 3)
 
276 
(84 – 708)
 
 
<3 
(<3 – 12)
 3)
 
4 
(<1 – 12)
 11)
 
4 
(<3 – 28)
 8)
 
8 
(<2 – 22)
 11)
 
<5 
 
7 
(2 – 37)
 
 
<1 
(<1 – 2)
 3)
 
168 
91 
(11 – 333)
 
 
<4 
(<4 – 7)
 3)
 
278 
(7 – 1298)
 
 
11 
(<3 – 16)
 6)
 
4 
(<1 – 16)
 11)
 
9 
(<3 – 16)
 7)
 
9 
(<2 – 40)
 9)
 
<5 
(<5 – 6)
 3)
 
7 
(1 – 41) 
<1 
(<1 – 2)
 3)
 
170 
102 
(50 – 421)
 
 
<4 310 
(66 – 1749)
 
 
<3 
(<3 – 13)
 4)
 
4 
(1 – 23)
 
 
6 
(<3 – 14)
 7)
 
8 
(<2 – 48)
 10)
 
<5 
(<5 – 10)
 2)
 
8 
(2 – 52)
 
 
<1 
(<1 – 2)
 3)
 
172 
165 
(59 – 769)
 
 
<4 416 
(184 – 2425)
 
 
5 
(<3 – 26)
 6)
 
6 
(1 – 27)
 
 
9 
(<3 – 25)
 9)
 
13 
(5 – 86)
 
 
<5 
(<5 – 6)
 3)
 
13 
(6 – 74)
 
 
<1 
(<1 – 1)
 2)
 
176 
230 
(68 – 1210)
 
 
<4 695 
(229 – 3484)
 
 
11 
(<3 – 26)
 10)
 
8 
(2 – 48)
 
 
14 
(<3 – 26)
 8)
 
22 
(3 – 92)
 
 
<5 
(<5 – 7)
 5)
 
20 
(7 – 119)
 
 
<1 
(<1 – 3)
 3)
 
192 
124 
(41 – 321)
 
 
<4 
(<4 – 8)
 3)
 
422 
(102 – 1103)
 
 
6 
(<3 – 14)
 8)
 
5 
(2 – 13)
 
 
10 
(<3 – 19)
 6)
 
8 
(<2 – 21)
 11)
 
<5 
 
11 
(5 – 24)
 
 
<1 
(<1 – 2)
 5)
 
 
Data are given as median (range). Data after multiple dose treatment (168-192h) shaded in grey. Number of footnote denotes number of subjects with 
quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 subject, 2) quantifiable concentrations in 2 subjects, etc. 
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Angiotensin peptide concentrations after single and multiple dose treatment 
After a single dose of the renin inhibitor aliskiren, concentrations of circulating Ang 1-10 
decreased to levels below the limit of quantification for most of the subjects and returned to 
predose concentrations after 24 hours. Despite the long half-life of aliskiren, this was also 
observed after multiple dosing (Figure 3A). Concentrations of circulating Ang 1-8 decreased, 
but remained above the LLOQ for most subjects and returned to baseline concentrations 
24 hours after dosing. Concentrations of the remaining analyzed peptides were mostly at or 
below the LLOQ (Table 2). Similar observations were made in RAS equilibrium analysis 
(Figure 4A) while equilibrium levels were more often detectable. 
Four and eight hours after 10 mg enalapril, median concentrations of circulating Ang 1-10 
increased approx. 5-fold compared to baseline and did not completely return to baseline 
24 hours after dosing. After multiple dosing a more pronounced increase (approx. 15-fold) of 
Ang 1-10 concentrations was observed (Figure 3B). Concentrations of circulating Ang 1-8 
decreased below baseline concentrations 2 hours after dosing and returned to baseline 
24 hours after dosing. After repeated enalapril doses, circulating concentrations of the ACE 
substrate Ang 1-7 increased to quantifiable concentrations (median 10-12 pg/ml, range 5-97 
pg/ml) between 2 hours and 8 hours after intake of the ACE inhibitor in 75% of the subjects 
(Table 2). In RAS equilibrium analysis, concentrations of Ang 1-10, Ang 1-8 and Ang 1-7 
were higher, but showed a similar pattern of changes compared to circulating peptide 
concentrations (Figure 4B). In addition, Ang 2-10 concentrations increased between 2 hours 
and 8 hours after single and multiple enalapril doses (Table 3). For the remaining peptides, 
no relevant changes of circulating or equilibrium concentrations were observed.  
Single and multiple dose treatment with the angiotensin receptor antagonist losartan led to a 
significant increase of circulating Ang 1-10 and Ang 1-8 concentrations without return to 
baseline values 24 hours after dosing (Table 2). RAS equilibrium analysis showed a similar 
pattern at a higher concentration level. After repeated dosing also a small increase of 
Ang 2-8 and Ang 3-8 concentrations was observed (Figure 4C, Table 3), with these 
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metabolites being more frequently above the LLOQ in contrast to circulating angiotensin 
levels. 
Ang 1-8 / Ang 1-10 ratios as a marker for ACE activity are shown in Figure 5. Without drug 
treatment, Ang 1-8 / Ang 1-10 ratios based on circulating peptide concentrations were 
1.1 (0.7) and did not show relevant variation during the 8-hour observation period. After 
single and multiple dose treatment with the ACE inhibitor enalapril, Ang 1-8 / Ang 1-10 ratios 
decreased significantly compared to predose ratios and did not return to baseline levels at 
the end of the 24 hour dose interval (Figure 5 B). The renin inhibitor and the angiotensin 
receptor antagonist had no relevant effect on the ratio (Figure 5A and 5C). 
Ang 1-8 / Ang 1-10 ratios based on equilibrium angiotensin levels were 2.0 (1.4) but showed 
comparable changes after ACE inhibition as the circulating peptide ratios (Figure 5D-5E). 
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 168 h 170 h 172 h 176 h 192 h 
Figure 3. RAS-Fingerprint graphs of 
circulating angiotensin concentrations after 
8 days of once-daily treatment with aliskiren 
150 mg (A), enalapril 10 mg (B), and losartan 
50 mg (C) before dosing (168h) and 2 hours 
(170h), 4 hours (172h), 8 hours (176h) and 
24 hours (192h) after the last dose. 
The diameter of the bubble corresponds to the 
median concentration (pg/ml), the numeric value of 
the median concentration is given below the 
peptide designation according to the number of 
amino acids in parenthesis. The arrows designate 
known degradation pathways with the responsible 
enzymes. ACE, angiotensin converting enzyme; 
AP, aminopeptidase A; DAP, dipeptidyl 
aminopeptidase; NEP, neutral endopeptidase. 
A) 
 
B) 
 
C) 
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168 h 170 h 172 h 176 h 192 h 
Figure 4. RAS-Fingerprint graphs of 
equilibrium RAS peptide concentrations after 
8 days of once-daily treatment with aliskiren 
150 mg (A), enalapril 10 mg (B), and losartan 
50 mg (C) before dosing (168h) and 2 hours 
(170h), 4 hours (172h), 8 hours (176h) and 
24 hours (192h) after the last dose. 
The diameter of the bubble corresponds to the 
median concentration (pg/ml), the numeric value of 
the median concentration is given below the 
peptide designation according to the number of 
amino acids in parenthesis. The arrows designate 
known degradation pathways with the responsible 
enzymes. ACE, angiotensin converting enzyme; 
AP, aminopeptidase A; DAP, dipeptidyl 
aminopeptidase; NEP, neutral endopeptidase. 
A) 
 
B) 
 
C) 
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Figure 5. Ratios of the ACE product Ang 1-8 and the ACE substrate Ang 1-10 after single and multiple dose treatment with the renin inhibitor 
aliskiren, the ACE inhibitor enalapril and the angiotensin receptor antagonist losartan. The Ang 1-8 / Ang 1-10 ratio reflects ACE activity and is 
significantly reduced after ACE inhibitor treatment while renin inhibition or angiotensin receptor blockade have no relevant effect. Ratios are based 
on circulating angiotensin concentrations (A-C) or equilibrium angiotensin concentrations (D-F). * p<0.001 
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
A
n
g
1
-8
/A
n
g
1
-1
0
 r
a
tio
s
(c
ir
cu
la
tin
g
 c
o
n
ce
n
tr
a
tio
n
s)
AliskirenA
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
A
n
g
1
-8
/A
n
g
1
-1
0
 r
a
tio
s
(e
q
u
ili
b
riu
m
 c
o
n
ce
n
tr
a
tio
n
s)
D
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
EnalaprilB
* * * * * *
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
E
* * * * * *
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
LosartanC
pr
ed
os
e 2h 4h 8h 24
h
16
8h
17
0h
17
2h
17
6h
19
2h
0.001
0.01
0.1
1
10
F
  
36 
Discussion 
 
In this study we quantified circulating and equilibrium concentrations of different 
renin-angiotensin system peptides in normotensive, non-salt-depleted healthy subjects. 
Concentrations were measured before and after single and multiple dose treatment with 
three drugs that inhibit the RAS cascade on different levels. 
Without treatment, concentrations of circulating Ang 1-10 and Ang 1-8 could be quantified in 
all study participants. The concentrations were in the low picomolar range and did not show 
time-dependent changes during the 8-hour baseline observation period. Concentrations of 
the remaining analyzed circulating angiotensin peptides were either below the limit of 
quantification or could only be quantified in a few study subjects. These observations are in 
line with the expected low activity of the blood pressure maintaining RAS system in 
normotensive subjects on a non-sodium-restricted diet. For Ang 1-10, Ang 1-8, Ang 2-10, 
Ang 2-8 and Ang 3-8 comparably low concentrations have been reported in healthy 
untreated subjects.[20, 22, 24, 31-33] For Ang 1-7 and Ang 1-9 reported values were either 
comparable with [34] or higher [35, 36]  than the concentrations we found in our study, which 
could be explained by an overestimation of values usually observed in antibody-based 
quantification methods. Ang 1-5 was previously only detected in equilibrium analysis in 
hemodialysis patients treated with ARBs [37] and was proposed as a surrogate marker for 
alternative RAS activation in the absence of ACE inhibition [38]. Ang 3-7 levels have not 
been published yet. 
Single doses of the renin inhibitor aliskiren, the ACE inhibitor enalapril and the angiotensin 
receptor antagonist losartan lead to characteristic and time-dependent changes of RAS 
peptide concentrations. Aliskiren caused a decrease of Ang 1-10 and Ang 1-8 while the 
already low concentrations of downstream angiotensin metabolites were not affected. The 
decrease of Ang 1-10 and Ang 1-8 did not last over the whole 24 hour dosing interval. 
Interestingly, this was not even the case under pharmacokinetic steady state conditions 
where AUC and Cmax of aliskiren increase approx. two-fold.[28] Comparable 
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dose-dependent effects of renin inhibitors on Ang 1-10 and Ang 1-8 concentrations have 
been reported in healthy subjects.[31, 39] After single and multiple dose treatment with 
aliskiren Ang 1-10 and Ang 1-8 concentrations decreased to approx. 25% and started to 
return to baseline levels between 6 hours and 10 hours after dosing.[31] 
In contrast to aliskiren, inhibition of the RAS cascade with an ACE inhibitor one step further 
downstream caused a completely different RAS peptide profile. Concentrations of the two 
ACE substrates Ang 1-10 and Ang 1-7 increased while Ang 1-8 decreased. Concentrations 
of the remaining angiotensin peptides showed no quantifiable changes. A qualitatively similar 
but more pronounced pattern was observed after multiple dose treatment. The ACE inhibitor 
treatment was the only one that caused an increase in circulating Ang 1-7 concentrations, 
with even more prominent effects in RAS equilibrium analysis. After single or multiple dose 
treatment with 20 mg enalapril comparable changes of Ang 1-10, Ang 1-8 [19, 31] and 
Ang 1-7 [34] concentrations have been described previously. No significant changes were 
found for Ang 2-8 and Ang 3-8, while for  Ang 2-10 approx. 10-fold higher concentrations 
were found in equilibrium analysis, indicating that like Ang 1-10, Ang 2-10 is a substrate for 
C-terminal conversion via ACE.[19]  
Blockade of the angiotensin receptor led to an angiotensin peptide pattern which was distinct 
from the patterns observed after renin or ACE inhibition. Already after the first dose, 
Ang 1-10 and Ang 1-8 concentrations increased and did not return to baseline within 
24 hours. Again, these changes were more pronounced after multiple dose treatment and 
they correspond well with published changes of Ang 1-10 and Ang 1-8 concentrations after 
treatment with losartan.[40]  
The observed changes of circulating and equilibrium angiotensin peptide concentrations 
were specific for the three different RAS inhibitors and correlated with drug concentrations in 
plasma. Maximal effects were observed 4 to 8 hours after dosing, corresponding to maximal 
drug concentrations in plasma. Twenty-four hours after a single dose, drug concentrations in 
plasma had decreased to levels of 10 ng/ml or below and RAS peptide concentrations had 
returned to baseline (aliskiren) or close to baseline levels (enalapril, losartan). After 8 days of 
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repeated daily dosing the characteristic changes of the angiotensin peptide profiles observed 
after single dose treatment were preserved or even more pronounced. This could be 
explained by enhanced renin feedback regulation resulting in increased angiotensin levels 
and a larger impact of pharmacological interference with the RAS. 
The ratio of the ACE product Ang 1-8 and the ACE substrate Ang 1-10 allows direct 
assessment of ACE activity. While renin inhibition or angiotensin receptor blockade had no 
relevant effect on the Ang 1-8 / Ang 1-10 ratio, the ACE inhibitor enalapril significantly 
decreased the ratio, indicating efficient blockade of ACE activity. This was also the case after 
multiple dose treatment and low Ang 1-8 / Ang 1-10 ratios thus could be used as a marker for 
ACE inhibitor treatment. This of course raises the question whether RAS inhibitor induced 
changes of angiotensin peptide concentrations are maintained over a longer period of time. 
Data from a small number of patients with essential hypertension continuously treated with 
ramipril suggest that the characteristic ACE inhibitor induced changes of Ang 1-10 and 
Ang 1-8 concentrations will persist for two years and possibly even longer.[41] However, 
whether the ratio also can be used to assess patients under long-term ACE inhibitor 
treatment will have to be tested in subsequent studies. 
After single and multiple dose treatment, the RAS inhibitor specific changes observed for 
circulating angiotensin peptides is reflected in equilibrium analysis. Compared to circulating 
concentrations, equilibrium angiotensin levels were several-fold higher and additional 
peptides such as Ang 2-10 (after ACE inhibition) or Ang 2-8 and Ang 3-8 (after angiotensin 
receptor blockade) reached quantifiable concentrations. Thus, although circulating 
angiotensin peptide concentrations may intuitively be thought to better reflect the 
intravascular situation, equilibrium peptide profiles surprisingly deliver the same qualitative 
information on the circulating RAS, while having the advantage of easier sampling and 
quantification combined with additional information related to RAS blocker pharmacology. 
 
A strength of our study is that it not only provides simultaneous and accurate quantification of 
angiotensin peptides with known biological functions such as Ang 1-8 and Ang 1-7, but also 
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of smaller less well characterized downstream peptides. For those angiotensin peptides, 
where published concentration ranges in normotensive subjects are available, we found 
good agreement between concentrations determined in our study and established values 
obtained by quantification approaches including HPLC fractionation. The short observation 
period and the healthy normotensive study population are limitations of our study that do not 
allow extrapolation of the results to patients with arterial hypertension with or without 
established RAS inhibitor treatment. 
 
In conclusion we have shown that in normotensive subjects single dose treatment with a 
renin inhibitor, an ACE inhibitor or an angiotensin receptor antagonist causes characteristic 
changes of circulating angiotensin peptide profiles which directly reflect the mechanism of 
action of the different RAS inhibitors. The changes are preserved after multiple dose 
treatment for one week. The drug-specific pattern of changes in circulating angiotensin 
peptide concentrations is also reflected in RAS equilibrium analysis. Compared to circulating 
RAS peptides equilibrium peptide levels are higher and show additional drug-specific 
changes in small downstream angiotensin metabolites. The present data suggest that RAS 
equilibrium analysis could be of value for the assessment of patients under RAS inhibitor 
treatment. Their potential as possible biomarkers in such patients has to be assessed in 
subsequent studies. 
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Supplementary 
 
Supplementary Table 1: Pharmacokinetic parameters of aliskiren, enalaprilat, and losartan carboxylic acid (E-3174) in 
plasma after single and multiple dose treatment. 
 Aliskiren Enalaprilat E-3174 
single dose multiple dose single dose multiple dose single dose multiple dose 
Cmax  
(ng/ml) 
40.8  29.3 39.3  22.4 24.6  12.8 28.1  8.2 182.3  69.0 174.8  58.8 
tmax 
 (h) 
1 (1 – 4) 1 (1 – 4) 4 (2 – 8) 4 (2 – 4) 4 (4 – 8) 4 (4 – 8) 
AUC0-24  
(ng/ml*h) 
194.4127.0 218.563.9 212.041.4 262.351.3 
1684.0 
672.3 
1603.1 
410.8 
t½  
(h) 
15.4  9.9 17.4  15.0 5.5  1.5 5.7  1.3 5.1  1.4 4.5  1.0 
 
Data are presented as meanSD (n = 12), data for tmax are presented as median and range. Cmax, 
maximal plasma concentration; tmax, time to reach maximal plasma concentration; AUC0-24, area 
under effect curve from time 0 to 24 hours; t1/2, half-life; E-3174, losartan carboxylic acid. 
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Supplementary Table 2:  Lower limits of quantification (LLOQ) for different angiotensin 
peptides 
 
 
Protease inhibitor analysis 
(pg/ml) 
Equilibrium analysis 
(pg/ml) 
Ang 1-10  5 5 
Ang 1-9  4 4 
Ang 1-8  1 2 
Ang 1-7  3 3 
Ang 1-5  1 1 
Ang 2-10  3 3 
Ang 2-8  2 2 
Ang 2-7  4 5 
Ang 3-8  1 1 
Ang 3-7  1 1 
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3.2 RAS peptide profiles in patients with primary arterial 
hypertension 
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Abstract 
 
Background Important effectors of the renin-angiotensin system (RAS) are small bioactive 
peptides like angiotensin II (Ang 1-8) or Ang 1-7. Ang 1-8 as the main effector of the RAS is 
involved in the development of arterial hypertension and progression of vascular disease. 
Some antihypertensive drugs that are recommended as first line treatment, such as ACE 
inhibitors or angiotensin receptor antagonists act on key enzymes or receptors of the RAS, 
and are expected to cause drug-type specific changes of RAS peptide concentrations. The 
objective of this study was to assess equilibrium angiotensin profiles in patients with 
treatment naïve primary arterial hypertension before and after 4 weeks of treatment with 
intermediate and high doses of the ACE inhibitor perindopril, the angiotensin receptor 
antagonist olmesartan, the calcium channel antagonist amlodipine, the thiazide diuretic 
hydrochlorothiazide. 
Methods In a single-center, open-label, randomized, parallel group study in 80 patients with 
arterial hypertension treatment was initiated with either a daily intermediate dose 
monotherapy of perindopril, olmesartan, amlodipine, or hydrochlorothiazide for at least 
4 weeks and, if the blood pressure target was not reached within that period, with a high 
dose monotherapy for another 4 weeks. Concentrations of antihypertensive drugs and 
angiotensin peptides were determined from standard lithium heparin aliquots using a liquid 
chromatography-tandem mass spectrometry method. Hemodynamic parameters were 
assessed noninvasively using  thoracic electrical bioimpedance (HOTMAN® System). 
Results In untreated patients with arterial hypertension, plasma angiotensin concentrations 
were in the mid picomolar range. Multiple dose treatment caused drug-specific changes of 
angiotensin peptide profiles which directly reflect the mechanism of action of the different 
RAS inhibitors. The ACE inhibitor perindopril increased concentrations of the ACE substrate 
angiotensin I (Ang 1-10). The angiotensin receptor antagonist olmesartan, the calcium 
channel antagonist amlodipine and the diuretic hydrochlorothiazide increased concentrations 
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of Ang 1-10 and Ang 1-8. None of the treatments led to a significant change in the evaluated 
hemodynamic parameters (CI and SSVRI). 
Conclusion Equilibrium angiotensin profiles show drug-specific changes which directly 
reflect the mechanism of action of the different RAS inhibitors perindopril and olmesartan. 
Amlodipine and hydrochlorothiazide, which do not interfere directly with the RAS cascade, 
show a pattern of RAS peptide profiles similar to olmesartan. The present data suggest that 
RAS equilibrium analysis could be of value for the assessment of patients under RAS 
inhibitor therapy. Their potential as possible biomarkers in patients will have to be assessed 
in additional studies. 
 
 
Introduction 
 
Angiotensin II (Ang 1-8) is the main effector of the renin-angiotensin aldosterone system 
(RAS) and is involved in the development of arterial hypertension and progression of 
cardiovascular disease. Ang 1-8 acts mainly through angiotensin II type 1 receptors (AT1). 
The AT1 is ubiquitously expressed in the cardiovascular system mediating vasoconstriction, 
stimulation of aldosterone and antidiuretic hormone release, inflammation, cardiac 
hypertrophy, vascular proliferation, and oxidative stress.[1, 2] On the other hand, Ang 1-7, 
with its counter-regulatory effects, is assumed to play a beneficial role on endothelial function 
and thus cardiovascular performance. Ang 1-7 binds specifically to the G-protein coupled 
receptor MAS and thereby opposes the AT1 mediated effects of Ang 1-8.[2, 3] The opposing 
cardiovascular effects of Ang 1-7 include vasodilation, vascular protection and 
anti-proliferation. Also anti-fibrinogenic, anti-thrombogenic and anti-arrythmogenic effects are 
described to be mediated by activation of receptor MAS1.[4-6] Similar counter-regulatory 
effects are mediated by binding of Ang 1-8 to the angiotensin II type 2 receptor (AT2) 
showing low expression in healthy adults but can be up-regulated under pathologic 
conditions such as hypertension.[1] 
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In recent years, several mass spectrometry based methods have been developed for the 
quantification of angiotensin peptides in human plasma.[7-11] According to their different 
mechanisms of action, ACE inhibitors and angiotensin receptor antagonists cause 
characteristic concentration changes of Ang 1-10 and Ang 1-8. Simultaneous quantification 
of multiple RAS peptides may provide drug-type specific RAS peptide profiles that could be 
useful for the assessment of patients under RAS inhibitor treatment. 
In clinical practice there is no uniform agreement which of the antihypertensive drugs that are 
recommended as first line treatment by European Society of Hypertension should be given 
for initial therapy. Relative efficacy of antihypertensive drugs in lowering blood pressure is 
30 to 50 percent, however, wide interpatient variability is observed and there are few clinical 
parameters that reliably can predict success of individual responses to the different drugs 
including ACE inhibitors, angiotensin receptor antagonists, calcium channel antagonists, and 
thiazide diuretics.[12] 
As a first step, we therefore characterized equilibrium angiotensin profiles in patients with 
treatment naïve primary arterial hypertension before and after 4 weeks of treatment with 
intermediate and high doses of the ACE inhibitor perindopril, the angiotensin receptor 
antagonist olmesartan, the calcium channel antagonist amlodipine, the thiazide diuretic 
hydrochlorothiazide. 
 
 
Methods 
 
Clinical Study 
A single-center, randomized, open-label, parallel group study 
(ClinicalTrials.gov ID: NCT02449811) was performed at the Medical Outpatient Clinic at the 
University Hospital Basel, Switzerland. The study was approved by the local Ethics 
Committee (Ethikkommission Zentral- und Nordwestschweiz, EKNZ) and conducted in 
accordance with the principles of the Declaration of Helsinki. Patients with treatment-naïve 
grade I and grade II primary hypertension were randomized to one of four standard first-line 
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treatments issued by the European Society of Hypertension.[13] According to clinical 
practice, the first treatment period was a daily intermediate dose monotherapy of either 5 mg 
perindopril, 20 mg olmesartan, 5 mg amlodipine, or 25 mg hydrochlorothiazide for at least 
4 weeks.  Before initiation of antihypertensive drug therapy, blood samples for the 
assessment of baseline peptide profiles were collected and non-invasive hemodynamic 
measurements were performed. After at least 4 weeks, blood sampling for angiotensin 
profiles and drug concentrations, and non-invasive hemodynamic measurements were done 
before drug intake and 4 hours after observed drug intake. All patients who did not reach 
blood pressure targets after 4 weeks according to the 2013 ESH guidelines for the 
management of arterial hypertension continued in the second treatment period with doubled 
monotherapy drug dose (10 mg perindopril, 40 mg olmesartan, 10 mg amlodipine, or 50 mg 
hydrochlorothiazide) for another 4 weeks. On study days the patients were fasted (including 
consumption of alcoholic beverages) for 10 h before observed drug intake. A light breakfast 
was allowed after drug intake. No concomitant medication was allowed, except for the 
treatment of AEs. 
 
Study Measurements 
Venous blood samples were obtained by direct puncture before and 4 h after observed drug 
intake on day 28 (+ 7 days) of each treatment period. For RAS equilibrium analysis, blood 
was collected into standard lithium heparin tubes. Equilibrium angiotensin peptide levels 
were measured following 30 min of equilibration of conditioned Li-heparin plasma at 37°C 
and subsequent stabilization of equilibrium peptide levels. For the analysis of drug and renin 
concentrations blood was collected into EDTA tubes. All tubes were centrifuged within 
20 min at 1500 g for 10 min at 4°C and plasma was stored at -80°C until analysis. 
Hemodynamic parameters (volemia, inotropy and vasoactivity) were non-invasively assessed 
from the patients in supine position using the HOTMAN® System (Hemo Sapiens Medical 
Inc., Sedona, AZ, USA).  After 5 min of rest, 3 consecutive measurements spaced 2 min 
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apart were recorded together with blood pressure measurements at the time points of blood 
sample collection. 
Blood pressure and heart rate were recorded from the patients using a 
Mobil-O-Graph 24 h PWA Monitor (I.E.M. GmbH Stolberg Germany). Blood pressure was 
measured every 20 min during the day and evening (from 6:00 to 22:00) and every 30 min at 
night (from 22:00 to 06:00). Presence of at least 70 percent of measurements was 
considered as an acceptable 24 h blood pressure monitoring recording for our study. The 
mean systolic blood pressure, diastolic blood pressure and heart rate were calculated for 
24 h. 
 
Materials and Reagents 
Amlodipine, amlodipine-d4, hydrochlorothiazide, hydrochlorothiazide-13C15N2d2 
olmesartan, olmesartan-d6, perindoprilat and perindoprilat-d4 were purchased from Toronto 
Research Chemicals (Toronto, ON, Canada). Formic acid, acetic acid, high-performance 
liquid chromatography (HPLC)-grade methanol, acetonitrile, and water were purchased from 
Merck KGaA (Darmstadt, Germany). 
Stable isotope labeled internal standards for angiotensin metabolites and MS grade formic 
acid were purchased from Sigma-Aldrich (Vienna, Austria). LC-MS-grade water, methanol 
and acetonitrile were purchased from Fisher Scientific (Vienna, Austria). 
 
Measurement of Drug Concentrations 
Concentrations of amlodipine, hydrochlorothiazide, olmesartan, and perindoprilat, in plasma 
were determined by reversed-phase HPLC with tandem mass spectrometry (HPLC–MS/MS). 
Chromatographic separation was done on a Shimadzu HPLC system (Shimadzu AG, 
Reinach, Switzerland) coupled to a triple quadrupole tandem mass spectrometer (API4000 
Qtrap, ABSciex, Massachusetts, USA). Three different methods were developed to analyze 
the analytes. 
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Analysis of perindoprilat 
Fifty microliters aliquots of plasma were mixed with 150 μL of an internal standard solution 
(Methanol:acetonitril (1:1 v/v)) containing perindoprilat-d4 at a concentration of 50 ng/mL, 
vortex mixed for 30 seconds and centrifuged (3,220g for 30 min at 10°C). Fifty microliters 
deproteinized supernatant was injected directly into the HPLC–MS/MS system. Samples 
were concentrated and purified on a trap cartridge (EXP HALO C18, 4.6 x 5 mm, Optimize 
technologies, Oregon, USA) at a flow rate of 5 mL/min water supplemented with 1% formic 
acid. Perindoprilat was eluted on a KinetexTM XB-C18 analytical column (2.6 μm, 100 Å, 
50 x 2.1 mm) using a gradient of acetonitrile (mobile phase B) and water plus 1% formic acid 
(mobile phase A). The total run time was 3.3 min. Samples were quantified using peak area 
ratios. Perindoprilat and perindoprilat-d4 were analyzed using electrospray ionization with 
multiple reaction monitoring (MRM) in negative polarity mode. The applied mass transitions 
and retention times are illustrated in Table 1. The method was linear over a concentration 
range of 0.25-250 ng/mL. Concentrations were calculated by interpolation from a calibration 
curve. Quality control samples were analyzed throughout the sample analysis. 
 
Analysis of olmesartan and hydrochlorothiazide 
Fifty microliter aliquots of plasma were mixed with 150 μL of an internal standard solution 
(methanol plus 0.01% acetic acid) containing hydrochlorothiazide-13C15N2d2 (100 ng/mL), 
and olmesartan-d6 (25 ng/mL), vortex mixed for 30 seconds and centrifuged (3,220g for 
30 min at 10°C). Ten microliters deproteinized supernatant was injected directly into the 
HPLC–MS/MS system. The analytes were separated on an Atlantis dC18 analytical column 
(3µm, 100 x 2.1 mm, Waters, Massachusetts, USA) using a gradient of water (mobile phase 
A) and acetonitrile (mobile phase A) both supplemented with 0.01% acetic acid. The total run 
time was 3 min. Samples were quantified using peak area ratios. Olmesartan, 
olmesartan-d6, hydrochlorothiazide, and hydrochlorothiazide-13C15N2d2 were analyzed 
using electrospray ionization with multiple reaction monitoring (MRM) in negative polarity 
mode. The applied mass transitions and retention times are illustrated in Table 1. The 
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method was linear over a concentration range of 1-500 ng/mL. Concentrations were 
calculated by interpolation from a calibration curve. Quality control samples were analyzed 
throughout the sample analysis. 
 
Analysis of amlodipine 
Fifty microliter aliquots of plasma were mixed with 150 μL of an internal standard solution 
(methanol plus 0.01% acetic acid) containing amlodipine-d4 at a final concentration of 
10 ng/mL, vortex mixed for 30 seconds and centrifuged (3,220g for 30 min at 10°C). Fifty 
microliters deproteinized supernatant was injected directly into the HPLC–MS/MS system. 
Samples were concentrated and purified on a trap cartridge (EXP HALO C18, 4.6 x 5 mm, 
Optimizetechnologies, Oregon, USA) at a flow rate of 3 mL/min acetonitrile and water 
(80:20 v/v) supplemented 0.01% acetic acid. The analytes were separated on an Atlantis 
dC18 analytical column (3 µm, 100 x 2.1 mm, Waters, Massachusetts, USA) using a gradient 
of water (mobile phase A) and acetonitrile (mobile phase A) both supplemented with 0.01% 
acetic acid. The total run time was 3.5 min. Samples were quantified using peak area ratios. 
The analytes were analyzed using electrospray ionization with multiple reaction monitoring 
(MRM) in positive polarity mode. The applied mass transitions and retention times are 
illustrated in Table 1. The method was linear over a concentration range 1-500 ng/mL for 
amlodipine. Concentrations were calculated by interpolation from a calibration curve. Quality 
control samples were analyzed throughout the sample analysis. 
 
 
 
 
 
 
 
 
Table 1   
Analyt MRM [m/z] Retention time [min] 
Perindoprilat 339.1 → 167.8  1.04  
Perindoprilat-d4 343.1 → 167.8  
Hydrochlorothiazide 295.9 → 204.7 1.01 
Hydrochlorothiazide-13C15N2d2 301.1 → 207.7  
Olmesartan 445.2 → 148.9 1.34 
Olmesartan-d6 451.2 → 153.9  
Amlodipine 409.1 → 294.0 1.53 
Amlodipine-d4 413.1 → 297.9  
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Quantification of RAS Peptide Concentrations  
Following 30 min of equilibration of conditioned Li-heparin plasma at 37°C, stabilized 
samples for quantification of angiotensin metabolite concentrations were spiked with stable 
isotope-labeled internal standards for each angiotensin metabolite (Ang 1-10, Ang 1-9, 
Ang 1-8, Ang 1-7, Ang 1-5, Ang 2-10, Ang 2-8, Ang 2-7, Ang 3-8, and Ang 3-7) at a 
concentration of 100 pg/ml. Following C18-based solid-phase-extraction, samples were 
subjected to LC-MS/MS analysis using a reversed-phase analytical column (Acquity UPLC® 
C18, Waters) operating in line with a XEVO TQ-S triple quadrupole mass spectrometer 
(Waters) in MRM mode. Internal standards were used to correct for peptide recovery of the 
sample preparation procedure for each angiotensin metabolite in each individual sample. 
Angiotensin metabolite concentrations were calculated considering the corresponding 
response factors determined in appropriate calibration curves in original sample matrix, on 
condition that integrated signals exceeded a signal-to-noise ratio of 10. Lower limits of 
quantification (LLOQ) for the different angiotensin peptides were between 1 and 5 pg/ml 
(Supplementary Table 1). 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism, version 7.01 (GraphPad Sofware, 
Inc., USA). Normal distribution of the data was assessed using D’Agostino-Pearson omnibus 
test. Parameters with a normal distribution were tested using one-way analysis of variance 
(ANOVA). Post-hoc analysis of significant overall results was done with Tukey-Kramer’s test 
for multiple comparisons. Non-normally distributed parameters were analyzed by the 
non-parametric Kruskal-Wallis test and Friedman test, respectively, in case of paired groups. 
For post-hoc analysis of significant overall results Dunn’s test for multiple comparisons was 
used. 
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Results 
Patients 
Table 2. Demographics and patients characteristics (N = 44). 
Sex, % (n)  
Male 29 (66%) 
Female 15 (34%) 
Age, years 50 (24 – 76) 
BMI, kg/m
2
 27 (19 – 35) 
Ethnic race  
Caucasian 41 (93%) 
Black 1 (2.3%) 
American 1 (2.3%) 
Asian 1 (2.3%) 
Ambulatory Daytime BP  
SBP, mmHg 141 (128 – 168) 
DBP, mmHg 89 (72 – 103) 
Heart rate, bmp 78 (52 – 102) 
Data are presented as number (percentage) for categorical 
variables and median (range) for continuous variables. 
 
A subgroup of 44 patients with treatment-naive primary arterial hypertension recruited from 
the Medical Outpatient Clinic at the University Hospital Basel, Switzerland between 
April 2015 and October 2016 was evaluated. In all patients diagnosis of arterial hypertension 
was confirmed by a 24 hour ambulatory blood pressure measurement. Demographic data of 
the study patients are given in Table 2. Forty-one patients were of Caucasian ethnicity, one 
patient was of African, one of American and another patient of Asian descent. They all had 
no history of relevant disease or drug abuse and no clinically relevant findings on laboratory 
tests (including renal and hepatic function) or electrocardiograms. Mean systolic daytime 
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blood pressure on ambulatory 24 hour blood pressure monitoring was 141 mmHg and mean 
diastolic daytime blood pressure was 89 mmHg. 
 
Clinical Study 
Patients with a new diagnosis of arterial hypertension were screened. One patient dropped 
out after randomization but before treatment was started. Twelve patients were randomized 
to perindopril, eleven to olmesartan, nine to amlodipine and eleven to hydrochlorothiazide. 
Therapeutic success according to the 2013 ESH guidelines for management of arterial 
hypertension [13] was defined as 24 h blood pressure measurements below the criteria of 
hypertension, i.e. mean SBP/DBP ≤ 130/80 mmHg on average, ≤ 135/85 during the day, OR 
≤ 120/70 during the night. After the first treatment period 18 patients (42%) had reached the 
blood pressure goal on an intermediate dose of perindopril, olmesartan, amlodipine, or 
hydrochlorothiazide. Of the remaining 25 patients, only 4 patients (16%) reached blood 
pressure goal after the second treatment period despite being treated with a two-fold higher 
dose compared to the first treatment period. In the perindopril group, 7 (58%) patients had 
reached the blood pressure goal after treatment period 1 (Table 3). Of the 5 remaining 
patients, 2 patients reached blood pressure goal after second treatment period, 1 patient did 
not reach blood pressure goal and 2 patients had to stop drug treatment due to adverse 
events (dizziness, swollen hands).  
In the olmesartan group, 7 (64%) patients had reached blood pressure goal after treatment 
period 1. Of the 4 remaining patients, 3 patients did not reach blood pressure goal and one 
patient had to stop drug treatment due to adverse effects (dizziness). In the amlodipine 
group, only 2 (22%) patients reached blood pressure goal after treatment period 1. Of the 
7 remaining patients, 2 patient reached blood pressure goal after second treatment period, 
3 patients did not reach blood pressure goal and 2 patients had to stop drug treatment due to 
adverse events (dizziness, exanthema). In the hydrochlorothiazide group, also only 2 (18%) 
patients reached blood pressure goal after treatment period 1. Of the 9 remaining patients, 
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none of the patients reached blood pressure goal after the second treatment period and 
2 patients had to stop drug treatment due to dizziness. 
 
Table 3. Proportion of patients reaching blood pressure goal. 
 BP goal reached Drop outs 
 YES NO  
Treatment period 1 (N = 43)    
overall 18 (42%) 25 (58%) - 
Perindopril, 5 mg 7 (58%) 5 (42%) - 
Olmesartan, 20 mg 7 (64%) 4 (36%) - 
Amlodipine, 5 mg 2 (22%) 7 (78%) - 
Hydrochlorothiazide, 25 mg 2 (18%) 9 (82%) - 
Treatment period 2 (N = 25)    
overall 4 (16%) 14 (56%) 7 (28%) 
Perindopril, 10 mg 2 (40%) 1 (20%) 2 (40%) 
Olmesartan, 40 mg 0 3 (75%) 1 (25%) 
Amlodipine, 10 mg 2 (29%) 3 (42%) 2 (29%) 
Hydrochlorothiazide, 50 mg 0 4 (78%) 2 (22%) 
Data are presented as number (percentage). 
 
Blood pressure changes 
Average decrease of systolic blood pressure of patients reaching the blood pressure goal 
after treatment period 1 was 21, 18, 14, 11 mmHg for perindopril, olmesartan, amlodipine, 
hydrochlorothiazide, respectively (Figure 1). In the perindopril group, of the 3 patients who 
did not reach blood pressure goal 1 patient showed an increase of mean SBP and DBP of 
3 mmHg and 5 mmHg, respectively, after dose increase in treatment period 2. This patient 
already showed a decrease of mean SBP/DBP of only 2/1 mmHg in treatment period 1. The 
patient who had to stop drug treatment due to dizziness after the dose was doubled showed 
a predominantly diastolic decrease of average SBP/DBP of 1/11 in treatment period 1. The 
patient, who had to stop drug treatment due to swollen hands, did respond to intermediate 
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dose treatment (decrease of SBP/DBP of 25/11 mmHg). In the olmesartan group, of the 
4 patients who did not reach blood pressure goal, 2 patients did respond to intermediate 
dose treatment with a decrease of mean SBP/DBP of 16/6 mmHg and 21/9 mmHg, 
respectively, and on high dose treatment with an additional decrease of mean SBP/DBP of 
4/3 mmHg and 11/4 mmHg. The patient who had to stop drug treatment due to dizziness 
after the dose was doubled showed a decrease of SBP/DBP of 22/8 mmHg on average, of 
26/10 mmHg at daytime and of 14/5 mmHg at nighttime while on intermediate dose 
treatment. One patient erroneously received high dose treatment in treatment period 1. No 
treatment period 1 data are available for this patient and he was excluded from the analysis 
Figure 1. 
 
Figure 1. Average 24 h systolic (SBP) and diastolic (DBP) blood pressure of patients at 
baseline (BL) and after treatment with a daily intermediate dose monotherapy of A) 
perindopril, B) olmesartan, C) amlodipine, D) hydrochlorothiazide (HCT) for at least 4 weeks 
(treatment period 1, TP1) and, if necessary,  with a high dose monotherapy for another 
4 weeks (TP2). Note: For therapeutic success according to the 2013 ESH guidelines for 
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management of arterial hypertension patients also had to fulfil criteria for daytime 
(SBP/DBP ≤ 130/80 mmHg) and nighttime (≤ 120/70) blood pressure. 
In the amlodipine group, of the 5 patients who did not reach blood pressure goal, 2 patients 
responded to intermediate dose treatment with a decrease of average SBP/DBP of 
18/5 mmHg and to high dose treatment with a further decrease of mean SBP/DBP of 
6/5 mmHg. One patient responded to intermediate dose treatment with an increase in SBP 
(4 mmHg) and a decrease in DBP (5 mmHg) and to high dose treatment with a decrease of 
average SBP/DBP of 8/7 mmHg. The patient who had to stop drug treatment due to 
dizziness after the dose was doubled showed a decrease of SBP/DBP of 4/4 mmHg on 
average. The patient who had to stop drug treatment due to exanthema after the dose was 
doubled showed no change of SBP/DBP on average. One patient responded to intermediate 
dose treatment with an increase of average SBP/DBP of 22/2 mmHg and to high dose 
treatment with a decrease of average SBP/DBP of 46/13 mmHg. In the hydrochlorothiazide 
group, none of the 9 patients reached blood pressure goal after the second treatment period 
and 2 patients had to stop drug treatment due to dizziness. 
 
Antihypertensive drug concentrations 
Plasma concentrations after once daily intermediate or high dose monotherapy with 
perindopril (5/10 mg), olmesartan (20/40 mg), amlodipine (5/10 mg) and hydrochlorothiazide 
(25/50 mg) are shown in Table 4 and Figure 2. 
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Figure 2. Plasma concentration of A) perindoprilat (5 mg / 10 mg), B) olmesartan (20 mg / 
40 mg), C) amlodipine (5 mg / 10 mg), D) hydrochlorothiazide (25 mg / 50 mg) after once 
daily treatment for 4 weeks. Ranges of published steady-state trough and 4 hour post dose 
drug concentrations are given next to the individual drug concentrations. 
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Table 4. Plasma concentrations of perindoprilat, olmesartan, amlodipine and 
hydrochlorothiazide after 4 weeks repeated once daily dosing before (Ctrough) and 4 hours 
after observed drug intake. 
Antihypertensive Drug Treatment Plasma concentration (ng/ml) 
 Cthrough 4 h 
Perindoprilat, 5 mg 2.3 (1.4 – 5.1) 9.4 (3.4 – 12.4) 
Perindoprilat, 10 mg 3.4 (2.7 – 5.3) 17.2 (15.5 – 18.4) 
Olmesartan, 20 mg 27 (10 – 60) 409 (285 – 1110) 
Olmesartan, 40 mg 51 (50 – 86) 1050 (928 – 1440) 
Amlodipine, 5 mg 4.5 (2.5 – 10.3) 6.3 (5.1 – 14.5) 
Amlodipine, 10 mg 9.5 (7.0 – 13.3) 13.5 (10.0 – 20.3) 
Hydrochlorothiazide, 25 mg 18.3 (7.7 – 26.9) 21.5 (15.4 – 55.9) 
Hydrochlorothiazide, 50 mg 117.0 (82.8 – 378.0) 268.5 (103.0 – 439.0) 
Data are presented as median (range). 
 
In 2 patients there was no increase in perindoprilat plasma concentration after observed drug 
intake. The values were confirmed by re-analysis of the samples. However, treatment lead to 
a decrease in average SBP/DBP from 154/96 mmHg and 150/81 mmHg to 129/85 mmHg 
and 126/74 mmHg, respectively. In 2 patients there was no increase in measured amlodipine 
plasma concentration after observed drug intake; however, both patients did reach BP goals 
after intermediate dose monotherapy. In 4 patients there was no increase in measured 
hydrochlorothiazide plasma concentrations after observed drug intake. Furthermore, in 2 of 
these patients there was no increase after one treatment period but an increase after the 
other. One patient showed no increase after both treatment periods. 
 
Angiotensin peptide concentrations in treatment-naïve primary arterial hypertension 
Before start of treatment, concentrations of equilibrium angiotensins as well as renin and 
aldosterone concentrations in patients with primary arterial hypertension were stable over 
2 weeks and in the same range as concentrations measured in normotensive healthy 
subjects (NCT01771783) and 10 sex and age matched healthy control subjects. At 
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pre-baseline assessment (conducted two weeks before baseline assessment in a subgroup 
of patients), median equilibrium concentrations of Ang 1-10 and Ang 1-8 were 30 pg/ml 
(range 2-81 pg/ml) and 67 pg/ml (range range 7-169 pg/ml), respectively, in the morning and 
42 pg/ml (range 3-97 pg/ml) and 97 pg/ml (range 17-267 pg/ml), respectively, at noon. At 
baseline assessment, median concentrations of Ang 1-10 and Ang 1-8 were 37 pg/ml 
(range 2-145 pg/ml) and 60 pg/ml (range 9-330 pg/ml), respectively, in the morning and 
41 pg/ml (range 3-219 pg/ml) and 92 pg/ml (range 7-404 pg/ml), respectively, at noon. At 
baseline, concentrations of Ang 1-9, Ang 2-7 and Ang 3-7 were below the lower limit of 
quantification (LLOQ) in all patients, and concentrations of the remaining peptides (Ang 1-7, 
Ang 1-5, Ang 2-10, Ang 2-8, Ang 3-8) could only be quantified in a few subjects. There was a 
significant increase in Ang 1-10 and Ang 1-8 concentration at noon compared to values 
obtained in the morning in paired samples, while without pairing the concentration did not 
differ significantly. 
 
Angiotensin peptide concentrations after single and multiple dose treatment 
Multiple dose treatment with an intermediate dose of the ACE inhibitor perindopril led to a 
significant increase of Ang 1-10 concentrations without return to baseline values 24 hours 
after dosing (Figure 3). Median concentrations of Ang 1-8 decreased significantly below 
baseline concentrations 4 hours after dosing and returned to baseline 24 hours after dosing. 
Concentrations of the ACE substrate Ang 1-7 increased to quantifiable concentrations 
(median 14 pg/ml, range 4-90 pg/ml) 4 hours after intake of the ACE inhibitor in 54% (7/13) 
of the patients (Supplementary Table 2). In addition, Ang 2-10 concentrations increased 
4 hours after observed drug intake. For the remaining peptides, either no relevant changes of 
concentrations were observed or their values remained below the LLOQ. Multiple dose 
treatment with an intermediate dose of the angiotensin receptor antagonist olmesartan and 
the calcium channel antagonist amlodipine led to a significant increase of Ang 1-10 and 
Ang 1-8 concentrations without return to baseline values 24 hours after dosing for 
olmesartan (Figure 3). As a consequence of the very high Ang 1-8 levels, the concentration 
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of downstream peptides Ang 3-8, Ang 2-8 and Ang 1-5 were also elevated without returning 
to baseline values throughout 24 hours after dosing. Multiple dose treatment with an 
intermediate dose of the hydrochlorothiazide led to an increase of Ang 1-10 which was 
significant only 24 hours after dosing. Median concentrations of Ang 1-8 increased 
significantly above baseline concentrations 4 hours after dosing and returned to baseline 
24 hours after dosing (Figure 3). Ang 1-8 concentrations after multiple dose treatment with 
hydrochlorothiazide are higher than with amlodipine and significant higher compared to 
baseline values, but after drug intake the increase in Ang 1-8 concentrations is less for 
hydrochlorothiazide compared to amlodipine and compared to baseline values, not 
statistically significant. Multiple dose treatment with an intermediate dose of the angiotensin 
receptor antagonist olmesartan led to a significant increase of Ang 1-10 and Ang 1-8 
concentrations without return to baseline values 24 hours after dosing (Figure 3). This effect 
was much more pronounced in patients who reached blood pressure targets compared to 
patients who did not reach blood pressure targets. Such a difference between patients who 
reached blood pressure targets compared to patients who did not reach blood pressure 
targets was not present in the effects observed after multiple dose treatment with perindopril, 
amlodipine or hydrochlorothiazide. 
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Figure 3. Ang 1-10 and Ang 1-8 peptide concentrations without treatment (BL) and after 
treatment with a daily intermediate dose monotherapy (TP1) of A) perindopril, B) olmesartan, 
C) amlodipine, D) hydrochlorothiazide for at least 4 weeks 4 hours (TP1 4h) and 24 hours 
(TP1 24h) after dosing. 
Representative RAS-Fingerprint graphs in patients with arterial hypertension without 
treatment (baseline) including enzymes involved in formation or degradation of the measured 
RAS peptides is shown in Figure 4. 
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A) B) 
Morning Noon Morning Noon 
 
 
Figure 4. Angiotensin peptide concentrations in the morning and at noon at A) pre-baseline 
and B) baseline assessment. 
A) B) 
4 h 24 h 4 h 24 h 
    
C) D) 
4 h 24 h 4 h 24 h 
    
Figure 5. Angiotensin peptide concentrations after treatment with a daily intermediate dose 
monotherapy (TP1) of A) perindopril, B) olmesartan, C) amlodipine, D) hydrochlorothiazide 
for at least 4 weeks 4 and 24 hours after dosing. 
In the subgroup of patients where a pre-baseline assessment was done (n = 20) no relevant 
change in RAS peptide profiles assessed two weeks apart was observed. Bubble plots after 
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treatment with either perindopril (10 mg), olmesartan (20 mg), amlodipine (5 mg), or 
hydrochlorothiazide (25mg) are shown in Figure 5. 
 
Renin and aldosterone concentrations 
 
Figure 6. Aldosterone plasma concentrations at baseline (BL) and after treatment with a 
daily intermediate dose monotherapy (TP1) of A) perindopril, B) olmesartan, C) amlodipine, 
D) hydrochlorothiazide for at least 4 weeks 4 and 24 hours after dosing. Aldosterone plasma 
concentrations in direct comparison E) 4 hours and F) 24 hours after dosing. 
The renin feedback induced by ACE inhibitors and angiotensin receptor antagonists was 
observed for perindopril and olmesartan, respectively. A slight renin feedback was observed 
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for amlodipine and hydrochlorothiazide. In the perindopril and olmesartan group plasma 
aldosterone concentrations decreased 4 hours after dosing and returned to baseline values 
24 hours after dosing (Figure 6A-B). In the amlodipine and hydrochlorothiazide groups 
plasma aldosterone concentrations slightly increased 4 hours after dosing and returned to 
baseline values 24 hours after dosing (Figure 6C-D). As shown in Figure 7, there was no 
correlation of equilibrium Ang 1-8 plasma concentration and plasma aldosterone 
concentration. 
 
Figure 7. Aldosterone plasma concentration versus equilibrium Ang 1-8 concentrations after 
treatment with a daily intermediate dose monotherapy (TP1) of A) perindopril, B) olmesartan, 
C) amlodipine, D) hydrochlorothiazide for at least 4 weeks 4 hours (red dots) and 24 hours 
(blue dots) after dosing. 
 
The Ang 1-8 / Ang 1-10 ratio as a marker for ACE activity is shown in Figure 8. Without drug 
treatment, mean Ang 1-8 / Ang 1-10 ratios were 2.8 (sd 2.2) and 2.5 (sd 1.5) when assessed 
in the morning or at noon, respectively. After multiple dose treatment with the ACE inhibitor 
perindopril, the Ang 1-8 / Ang 1-10 ratio decreased significantly compared to baseline and 
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did not return to baseline levels at the end of the 24 hour dose interval (Figure 8). The 
angiotensin receptor antagonist, the calcium channel antagonist and hydrochlorothiazide on 
the other hand had no relevant effects on the Ang 1-8 / Ang 1-10 ratio (Figure 8). 
 
Figure 8. Ang 1-8 / Ang 1-10 at baseline (BL) and after treatment with a daily intermediate 
dose monotherapy (TP1) of A) perindopril, B) olmesartan, C) amlodipine, 
D) hydrochlorothiazide for at least 4 weeks 4 and 24 hours after dosing. Ang 1-8 / Ang 1-10 
ratio in direct comparison at E) 4 hours and F) 24 hours after dosing. 
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Cardiac Index and SSVRI 
 
Figure 9. Cardiac index and SSVRI without treatment (BL) and after treatment with a daily 
intermediate dose monotherapy (TP1) of A) perindopril, B) olmesartan, C) amlodipine, D) 
hydrochlorothiazide for at least 4 weeks 4 hours and 24 hours after dosing. 
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Organ perfusion is determined by the arterial blood pressure. In general, the arterial blood 
pressure is determined by the product of cardiac output (CO) and systemic vascular 
resistance (SVR). The cardiac index (CI) is the cardiac output indexed to patient’s body 
surface area. The systemic vascular resistance indexed to patient’s body surface area and 
measured per beat leads to stroke systemic vascular resistance (SSVRI) which is an index of 
vasoactivity. Comparison of measured CI and SSVRI showed stability during the day as well 
as stability over 2 weeks. None of the treatments led to a significant change in CI or SSVRI 
(Figure 9). 
 
 
Discussion 
 
It is known that only 40-50% of patients reach blood pressure targets on hydrochlorothiazide 
monotherapy and therapy is more successful in elderly patients and patients from African 
descent.[14, 15] Neutral or negative results for hydrochlorothiazide in the management of 
hypertension were reported by clinical trials before.[16] Nevertheless, ESH recommends 
thiazide diuretics as a first-line drug for the initiation of antihypertensive drug treatment based 
on data derived from multiple randomized clinical trials or meta-analyses. A systematic 
review by Musini et al. 2014 [17] revealed a mean systolic/diastolic blood pressure-lowering 
effect of 4/2 mmHg, 6/3 mmHg, 8/3 mmHg and 11/5 mmHg for hydrochlorothiazide doses of 
6.25 mg, 12.5 mg, 25 mg and 50 mg/day, respectively. Furthermore, thiazide diuretics were 
effective in the primary prevention of cardiovascular events. A further blood pressure 
decrease would be achieved by combination with a second antihypertensive agent. 
Drug exposure after repeated dosing was in line with published values, except for 
olmesartan.[18-23] Four hours after observed drug intake measured values were slightly 
higher than reported in literature.[19, 20] The lack of increase in some pharmacokinetic 
samples remained unclear. In case of concomitant medication drug-drug interactions were 
excluded. According to the case report forms all respective patients had been fasting. This is 
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relevant especially for perindopril as food has been shown to significantly reduce relative 
bioavailability of perindoprilat up to 35% +/- 42%.[24] 
 
In this study we quantified equilibrium concentrations of different angiotensin peptides in 
patients with primary arterial hypertension. Concentrations were measured before start of 
treatment and 4 or 8 weeks after multiple dose treatment with one of four drugs used as first 
line treatment. Without treatment, concentrations of Ang 1-10 and Ang 1-8 could be 
quantified in all study participants. Equilibrium angiotensin concentrations were in the mid 
picomolar range and Ang 1-10 and Ang 1-8 showed significant circadian changes. 
Concentrations of the remaining analyzed RAS peptides were either below the limit of 
quantification or could only be quantified in a few study participants. A significant increase of 
Ang 1-10 and Ang 1-8 at noon was not observed in normotensive healthy subjects 
(NCT01771783), but in this study the area under the effect curve from 0 to 24 hours of 
Ang 1-10 and Ang 1-8 at baseline was calculated and intra-individual changes in each 
peptide from morning to noon were not compared. If measured Ang 1-10 and Ang 1-8 
concentration between morning and noon measurement are compared regardless of paired 
values, the increase is no longer significant as the changes are small. Median values and 
range of Ang 1-10 and Ang 1-8 of patients with primary arterial hypertension are slightly 
higher than values measured in normotensive healthy subjects (NCT01771783). Although 
the renin-angiotensin system plays an important role in blood pressure regulation, there are 
additional primary factors determining blood pressure including the sympathetic nervous 
system, or the plasma volume. Furthermore, plasma levels of Ang 1-10 and Ang 1-8 may not 
correlate directly with tissue levels.[25] 
Multiple doses of the ACE inhibitor perindopril and the angiotensin receptor antagonist 
olmesartan, both inhibiting the RAS cascade on different levels, lead to the sane 
characteristic changes of RAS peptide concentrations observed previously in normotensive 
healthy subjects (NCT01771783). After multiple dose treatment with an intermediate dose of 
perindopril for 4 weeks, the ACE inhibitor produced a significant increase of Ang 1-10. In 
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normotensive healthy subjects the ACE inhibitor also caused an increase in the ACE 
substrate Ang 1-7. This was also observed in patients with arterial hypertension. After 
multiple dose treatment with an intermediate dose of olmesartan for 4 weeks, the angiotensin 
receptor antagonist produced a significant increase of both Ang 1-10 and Ang 1-8. The 
changes in Ang 1-10 and Ang 1-8 equilibrium concentrations were maintained to a significant 
extent over the whole 24 hour dosing interval for perindopril and olmesartan. 
The multiple dose treatment with an intermediate dose of amlodipine, a calcium channel 
antagonist, for 4 weeks led to a significant increase in Ang 1-10 and Ang 1-8 as observed 
after treatment with olmesartan and the changes of Ang 1-10 and Ang 1-8 equilibrium 
concentrations were maintained over the whole 24 hour dosing interval as well. However, the 
observed changes were statistically not significant. After multiple dose treatment with an 
intermediate dose of hydrochlorothiazide for 4 weeks, also the diuretic produced an increase 
in Ang 1-10 and Ang 1-8, but only the increase in Ang 1-8 was statistically significant. While 
the changes of Ang 1-8 were maintained over the whole 24 hour dosing interval (but not to a 
significant extent), the changes of Ang 1-10 were only significant at the end of the 24 hour 
dosing interval. This might reflect the slow mechanism of action of hydrochlorothiazide. 
Olmesartan treatment resulted in a significant reduction in plasma aldosterone levels, which 
is in line with previous findings reported by Nakamura et al. 2009.[26] However, for none of 
the four drugs a direct relationship between Ang 1-8 and aldosterone concentration was 
observed. Besides Ang 1-8, also potassium is a main regulator of aldosterone.[27] High 
plasma concentrations of Ang 1-8 or potassium increase aldosterone production. But a low 
blood volume or low sodium levels, in turn, regulate Ang 1-8 concentrations. In addition, 
there are other factors such as adrenocorticotrophin (ACTH) and a local renin-angiotensin 
system in the zona glomerulosa of the adrenal glands that also influence aldosterone 
production.[27, 28] 
The ratio of the ACE product Ang 1-8 and the ACE substrate Ang 1-10 can be used as a 
marker of ACE activity. While angiotensin receptor and calcium channel blockade or 
hydrochlorothiazide had no relevant effect on the Ang 1-8 / Ang 1-10 ratio, it was significantly 
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decreased by the ACE inhibitor perindopril. This was also observed after multiple dose 
treatment with enalapril in healthy normotensive subjects (NCT01771783) and low 
Ang 1-8 / Ang 1-10 ratios thus could be used as a marker for ACE inhibitor treatment.  
RAS inhibitor induced changes of angiotensin peptide concentrations are maintained over a 
period of up to 8 weeks. Data from a small number of patients with essential hypertension 
continuously treated with ramipril suggest that the characteristic ACE inhibitor induced 
changes of Ang 1-10 and Ang 1-8 concentrations may persist for up to two years and 
possibly even longer.[29] However, whether the ratio can be used to assess patients under 
long-term ACE inhibitor treatment will have to be tested in subsequent studies. 
 
A strength of our study is that it systematically quantifies equilibrium angiotensin peptide 
concentrations in patients with arterial hypertension before and after start of monotherapy 
treatment with first-line antihypertensive drugs with different mechanisms of action. The study 
provides essential baseline data which is required for the interpretation of drug-induced 
changes of RAS peptide concentrations in more complex patients. The short observation 
period and the absence of comorbidities in our study population are limitations of our study 
that do not allow extrapolation of the results to patients with arterial hypertension on 
long-term treatment and / or with comorbidities. 
 
In conclusion we have shown that characteristic changes of angiotensin peptide 
concentrations in serum observed after multiple dose treatment with an ACE inhibitor or an 
angiotensin receptor antagonist directly reflect the mechanism of action of these RAS 
inhibitors and that these changes are maintained after multiple dose treatment in patients 
with arterial hypertension. Furthermore we also showed that non-RAS inhibitors 
antihypertensive drugs which do not directly interfere with the RAS cause changes in 
equilibrium angiotensin concentrations with a pattern similar to the one observed for the 
angiotensin receptor antagonist. These changes are preserved after multiple dose treatment 
for up to eight weeks. The present data suggest that RAS peptide profiles may be useful 
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biomarkers to assess drug treatment efficacy in patients with arterial hypertension. RAS 
peptide profiles now need to be further characterized in subsequent studies in patients with 
arterial hypertension under combination drug treatment as well as in patients with different 
comorbidities. 
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Supplementary 
 
Supplementary Table 1:  Lower limits of quantification (LLOQ) for 
different angiotensin peptides 
 
 
Equilibrium analysis 
(pg/ml) 
Ang 1-10  2 
Ang 1-9  2 
Ang 1-8  1 
Ang 1-7  2 
Ang 1-5  1 
Ang 2-10  1 
Ang 2-8  2 
Ang 2-7  1 
Ang 3-8  1 
Ang 3-7  1 
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Supplementary Table 2: RAS peptide concentrations (pg/ml) in equilibrium samples before (baseline) and after multiple doses of 
perindopril, olmesartan, amlodipine, hydrochlorothiazide. 
 
Pre-Baseline (n = 20)  
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
30 
(2 - 81) 
<2 
 
67 
(7 - 169) 
<1  
 
<1 
(<1 - 2) 
2) 
<1 
(<1 - 4) 
1) 
<2 
(<2 - 1) 
1)
 
<1 
 
2 
(<1 - 3) 
15) 
<1 
 
8 
(2 - 19) 
214 
(56 - 480) 
4 
42 
 (<2 - 97) 
18) 
<2 
 
99 
(<1 - 267) 
18) 
<2 
 
<1 
(<1 - 2) 
5)
 
<1 
 
<2 
(<2 - 2) 
1)
 
<1 
 
2 
(<1 - 4) 
15)
 
<1 
 
10 
(1 - 45) 
199 
(30 - 540) 
 
Baseline (n = 43)  
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
37 
(<2 - 145) 
42)
 
<2 
 
60 
(9 - 330) 
<2 
 
<1 
(<1 - 3) 
14) 
<1 
(<1 - 7) 
7) 
<2 
(<2 - 3) 
2) 
<1 
 
2 
(<1 - 5) 
30) 
<1 
 
7 
(1 - 32) 
232 
(73 - 728) 
4 
41 
(3 - 219) 
<2 
 
92 
(7 - 404) 
<2 
(<2 - 6) 
7) 
<1 
(<1 - 6) 
14) 
<1 
(<1 - 8) 
7) 
<2 
(<2 - 8) 
9) 
<1 
 
2 
(<1 - 11) 
32) 
<1 
 
9 
(1 - 66) 
222 
(65 - 752) 
 
Perindopril, 5 mg (n = 12) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
289 
(21 - 546) 
<2 
 
72 
(9 - 252) 
<3 
(<2 - 20) 
6) 
<1 
(<1 - 5)
 5)
 
10 
(<1 - 38) 
10) 
<2 
(<2 - 3) 
2) 
<1 
 
2 
(<1 - 5)
 10) 
<1 
 
21 
(1 - 63) 
325 
(119 - 427) 
4 
448 
(35 - 2718) 
<2 
 
65 
(2 - 153) 
14 
(<2 - 90) 
7)
 
<1 
(<1 – 4) 
5)
 
12 
(<1 - 238) 
10) 
<2 
 
<1 
 
1 
(<1 - 5) 
9) 
<1 
 
37 
(1 - 127) 
213 
(86 - 423) 
 
Perindopril, 10 mg (n = 3) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
480 
(289 - 756) 
<2 
  
95 
(71 - 129) 
15 
(<2 – 21) 
2)
 
4 
(<1 - 4) 
2)
 
19 
(<1 - 19) 
2) 
<2 
 
<1 
 
2 
(<1 - 2) 
2) 
<1 
 
29 
(21 - 68) 
467 
(208 - 555) 
4 
1104 
(1081 - 
1954) 
<2 
 
38 
(27 - 99) 
62 
(<2 - 91) 
2)
 
<1 
(<1 - 5) 
1)
 
43 
(17 - 46) 
<2 
 
<1 
 
1 
(<1 - 2) 
2) 
<1 
 
60 
(48 - 174) 
198 
(156 - 274) 
 
Data are given as median (range). Number of footnote denotes number of patients with quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 
patient, 2) quantifiable concentrations in 2 patient, etc. 
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Supplementary Table 2 cont.: RAS peptide concentrations (pg/ml) in equilibrium samples before (baseline) and after multiple doses of 
perindopril, olmesartan, amlodipine, hydrochlorothiazide. 
 
Olmesartan, 20 mg (n = 10) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
268 
(20 - 778) 
<2 
 
455 
(70 - 1055) 
10 
(<2 - 25) 
6)
 
5 
(<1 – 15) 
8)
 
<2 
(<1 - 28) 
5) 
9 
(<2 - 17) 
6) 
<1 
 
9 
(<1 - 24) 
9) 
<1 
 
51 
(5 - 155) 
210 
(116 - 409) 
4 
407 
(55 - 2125) 
<2 
 
760 
(143 - 2230) 
<8 
(<2 – 38) 
5)
 
11 
(<1 – 26) 
9)
 
19 
(<1 - 49) 
6) 
21 
(<2 - 32) 
6) 
<1 
 
9 
(3 - 56) 
<1 
 
84 
(8 - 764) 
129 
(68 - 273) 
 
Olmesartan, 40 mg (n = 3) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
128.4 
(43 - 242) 
<2 
  
256 
(138 - 352) 
<2 
 
3 
(<1 – 3) 
2)
 
<1 
(<1 - 4) 
1) 
<2 
 
<1 
 
9 
(2 - 9) 
<1 
 
22 
(8 - 36) 
212 
(156 - 357) 
4 
348 
(56 - 556) 
<2 
 
612 
(203 - 924) 
7 
(<2 - 10) 
2) 
7 
(<1 - 7) 
2)
 
<1 
(<1 - 7) 
1) 
7 
(<2 - 9) 
2) 
<1 
 
19 
(3 - 21) 
<1 
 
41 
(10 - 72) 
89 
(79 - 189) 
 
Amlodipine, 5 mg (n = 9) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
35 
(11 - 126) 
<2 
  
108 
(42 - 274) 
<2 
 
<1 
(<1 - 4) 
4) 
<1 
(<1 - 2) 
1) 
<2 
(<2 - 4) 
2) 
<1 
 
3 
(<1 - 6) 
8) 
<1 
 
11 
(4 - 24) 
307 
(229 - 573) 
4 
52 
(26 - 187) 
<2 
 
146 
(67 - 479) 
<2 
(<2 - 4) 
2) 
3 
(<1 - 6) 
6)
 
<1 
(<1 - 3) 
3) 
<2 
(<2 - 5) 
3) 
<1 
 
4 
(<1 - 9) 
8) 
<1 
 
12 
(5 - 33) 
361 
(177 - 508) 
 
Amlodipine, 10 mg (n = 5) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
59 
(18 - 153) 
<2 
  
105 
(41 - 353) 
<2 
 
1 
(<1 - 5) 
3)
 
<1 
(<1 - 1) 
1) 
<2 
(<2 - 3) 
2) 
<1 
 
3 
(<1 - 6) 
4) 
<1 
 
13 
(8 - 26) 
361 
(219 - 500) 
4 
96 
(52 - 173) 
<2 
 
309 
(91 - 436) 
<2 
 
3 
(<1 – 4) 
4)
 
<1 
(<1 - 3) 
1) 
<2 
(<2 - 3) 
2) 
<1 
 
4 
(<1 - 6) 
4)
 
<1 
 
26 
(22 - 32) 
250 
(214 - 488) 
 
Data are given as median (range). Number of footnote denotes number of patients with quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 
patient, 2) quantifiable concentrations in 2 patient, etc. 
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Supplementary Table 2 cont.: RAS peptide concentrations (pg/ml) in equilibrium samples before (baseline) and after multiple doses of 
perindopril, olmesartan, amlodipine, hydrochlorothiazide. 
 
Hydrochlorothiazide, 25 mg (n = 11) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
71 
(8 - 359) 
<2 
  
173 
(36 - 642) 
<2 
(<2 - 13) 
2)
 
<1 
(<1 - 9) 
5)
 
<1 
(<1 - 8) 
3) 
<2 
(<2 - 9) 
3) 
<1 
 
4 
(<1 - 14) 
8) 
<1 
 
11 
(4 - 60) 
360 
(146 - 466) 
4 
95 
(16 - 714) 
<2 
 
195 
(58 - 1287) 
<2 
(<2 - 20) 
2) 
3 
(<1 - 17) 
6)
 
<1 
(<1 - 8) 
2) 
2 
(<2 - 17) 
6) 
<1 
 
6 
(<1 - 31) 
9) 
<1 
 
14 
(5 - 102) 
402 
(162 - 672) 
 
Hydrochlorothiazide, 50 mg (n = 7) 
Time (h) Ang 1-10 Ang 1-9 Ang 1-8 Ang 1-7 Ang 1-5 Ang 2-10 Ang 2-8 Ang 2-7 Ang 3-8 Ang 3-7 
Renin 
(ng/L) 
Aldosterone  
(pmol/L) 
0 
100 
(47 - 157) 
<2 
  
155 
(98 - 424) 
<2 
 
2 
(<1 - 4) 
5)
 
<1 
(<1 - 6) 
3) 
<2 
(<2 - 3) 
3) 
<1 
 
4 
(2 - 7) 
<1 
 
13 
(6 - 26) 
361 
(273 - 556) 
4 
133 
(58 - 443) 
<2 
 
267 
(85 - 600) 
<2 
(<2 - 4) 
2)
 
2 
(<1 - 4) 
6)
 
4 
(>1 - 12) 
5) 
3 
(<2 - 3) 
5) 
<1 
 
5 
(2 - 12) 
<1 
 
25 
(10 - 31) 
305 
(199 - 694) 
 
Data are given as median (range). Number of footnote denotes number of patients with quantifiable peptide concentrations, i.e: 1) quantifiable concentrations in 1 
patient, 2) quantifiable concentrations in 2 patient, etc. 
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3.3 RAS peptide profiles in patients with uncontrolled hypertension 
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Abstract 
 
Background Ang 1-8 is the main effector of the renin angiotensin system (RAS) and involved in 
the development of arterial hypertension and progression of vascular disease. Usually, patients 
with uncontrolled hypertension do have an antihypertensive drug in their drug combination 
acting on a key enzymes or receptors of the RAS, which cause drug-type specific changes of 
RAS peptide concentrations. The objective of this study was to assess equilibrium angiotensin 
profiles in patients with uncontrolled hypertension at a random time point and before and 
4 hours after observed drug intake. 
Methods In an observational single-center study 20 patients with uncontrolled hypertension 
concentrations of antihypertensive drugs and RAS peptides were determined using a liquid 
chromatography-tandem mass spectrometry method on a random time point, and before and 
4 hours after observed drug intake of the patients current antihypertensive drugs. Equilibrium 
angiotensin concentrations were determined from standard lithium heparin aliquots. 
Results In patients with uncontrolled hypertension drug-specific changes of angiotensin peptide 
profiles caused by different RAS inhibitors were present despite combined drug treatment with 
at minimum a calcium channel antagonist and a diuretic. Drug combinations including an ACE 
inhibitor increased concentrations of the ACE substrate angiotensin I (Ang 1-10) while reducing 
Ang 1-8 concentrations, resulting in a profound decrease of the Ang 1-8 / Ang 1-10-Ratio. Drug 
combinations including an angiotensin receptor antagonist increased concentrations of both, 
Ang 1-10 and Ang 1-8. 
Conclusion Equilibrium RAS peptide profiles show drug-specific changes, which directly reflect 
the mechanism of action of angiotensin receptor antagonists and ACE inhibitors. The present 
data suggest that RAS peptide profiles could be of value for the assessment of patients under 
RAS inhibitor therapy. Their potential as possible biomarkers in patients will have to be 
assessed in additional studies.  
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Introduction 
 
Resistant hypertension is defined as blood pressure that remains above goal in spite of 
concurrent use of 3 antihypertensive agents (including a diuretic) at optimal doses or if blood 
pressure control requires four or more medications.[1] In patients with apparent resistant 
hypertension differentiation between true resistant and pseudo-resistant hypertension is difficult. 
Reasons for a pseudo-resistant hypertension are white-coat hypertension, BP elevating 
co-medications, poor adherence, insufficient drug therapy, or secondary causes such as 
obstructive sleep apnea or primary aldosteronism. Several studies indicate that a considerable 
number of patients do not reach blood pressure goals and thus uncontrolled hypertension is a 
major clinical problem.[1-4] Patients with uncontrolled arterial hypertension are at greater risk of 
stroke, myocardial infarction, heart failure, and/or chronic kidney disease and the benefits of 
successful treatment are substantial.[5, 6] Moreover, literature indicates that non-adherence is 
one of the major causes of uncontrolled hypertension and therefore treatment failure.[7, 8] 
Detection and treatment of uncontrolled hypertension due to non-adherence is important to 
improve the management of these patients but few tools exist to accurately and routinely detect 
it. 
Recent studies confirmed reliable quantification of angiotensin peptides in human plasma and 
showed characteristic drug-type specific concentration changes of Ang 1-10 and Ang 1-8 after 
treatment with ACE inhibitors and angiotensin receptor antagonists (NCT01771783 and 
NCT02449811). In this study, we characterized equilibrium RAS peptide profiles in patients with 
uncontrolled arterial hypertension. In this setting RAS peptide profiles may add valuable 
information, which in combination with measured drug concentrations could help to differentiate 
between true drug resistance and non-adherence. 
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Methods 
 
Study Design 
An observational, exploratory single-center pilot study (ClinicalTrials.gov ID: NCT02962778) 
was performed at the Medical Outpatient and Hypertension Clinic, University Hospital Basel, 
Switzerland. The study was approved by the local Ethics Committee (Ethikkommission 
Nordwest- und Zentralschweiz) and conducted in accordance with the principles of the 
Declaration of Helsinki. 
In patients with uncontrolled hypertension referred to the Medical Outpatient and Hypertension 
Clinic blood samples for the assessment of RAS peptide profiles and antihypertensive drug 
concentrations were collected. Blood samples were collected once together with routine blood 
sampling at a clinical check up visit (random time point) as well as before and 4 hours after a 
planned observed drug intake. On the day of observed drug intake the patients were fasted for 
10 h before drug intake. A light breakfast was allowed after study drug intake. For the analysis 
of equilibrium angiotensin concentrations, blood was collected into standard lithium heparin 
tubes. Equilibrium angiotensin peptide levels were measured following 30 min of equilibration of 
conditioned Li-Heparin plasma at 37°C and subsequent stabilization of equilibrium peptide 
levels. For the analysis of drug concentrations blood was collected into EDTA tubes. All tubes 
were centrifuged within 30 min at 1500 g for 10 min at 4°C and plasma was stored at -80°C until 
analysis. 
Blood pressure and heart rate were recorded from the patients in sitting position for at least 
10 min using an automatic oscillometric device. Measurements were done at the time points of 
blood sample collection. At each time point, blood pressure and heart rate were measured three 
consecutive times with an interval of at least one minute between measurements and the 
average of the three readings was recorded. If two blood pressure readings differed by more 
than 5 mmHg the outlier was excluded for the calculation of the average.  
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Patient Population 
Patients aged ≥ 18 years of either gender referred to the Medical Outpatient and Hypertension 
Clinic of the University Hospital Basel, Switzerland were included. Uncontrolled hypertension 
was defined according to ESH guidelines as office blood pressure ≥ 140/90 mmHg and mean 
24 hour blood pressure > 130/80 mmHg on average, or > 135/85 mmHg during the day, or 
> 120/70 mmHg during the night, in spite of concurrent use of 3 antihypertensive agents at 
optimal doses, including a diuretic OR office blood pressure and 24 hour mean blood pressure 
controlled with four or more medications.[9] Patients had to qualify by 24 hour automatic blood 
pressure measurement. Prior to the qualifying ambulatory blood pressure measurement, drug 
treatment was unchanged for four weeks. Main exclusion criteria were a known secondary 
arterial hypertension at time of inclusion, history of, or clinically relevant or uncontrolled 
cardiovascular disease, and diagnosis of secondary hypertension after study inclusion. 
 
Materials and Reagents 
Amlodipine, amlodipine-d4, hydrochlorothiazide, hydrochlorothiazide-13C15N2d2 olmesartan, 
olmesartan-d6, perindoprilat, perindoprilat-d4, candesartan, candesartan-d5, metoprolol, 
metoprolol-d6, bisoprolol, bisoprolol-d5, lercanidipine, lercanidipine-d3, nebivolol, and nevivolol-
d4 were purchased from Toronto Research Chemicals (Toronto, ON, Canada). Formic acid, 
acetic acid, high-performance liquid chromatography (HPLC)-grade methanol, acetonitrile, and 
water were purchased from Merck KGaA (Darmstadt, Germany). 
Stable isotope labeled internal standards for angiotensin metabolites and MS grade formic acid 
were purchased from Sigma-Aldrich (Vienna, Austria). LC-MS-grade water, methanol and 
acetonitrile were purchased from Fisher Scientific (Vienna, Austria). 
 
Measurement of Drug Concentrations 
Concentrations of amlodipine, hydrochlorothiazide, olmesartan, perindoprilat, candesartan, 
metoprolol, bisoprolol, lercanidipine, and nebivolol in plasma were determined by reversed-
phase HPLC with tandem mass spectrometry (HPLC–MS/MS). Chromatographic separation 
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was done on a Shimadzu HPLC system (Shimadzu AG, Reinach, Switzerland) coupled to a 
triple quadrupole tandem mass spectrometer (API4000 Qtrap, ABSciex, Massachusetts, USA). 
Three different were developed to analyze the analytes. 
 
Perindoprilat, olmesartan, amlodipine and hydrochlorothiazide were analyzed as described in 
chapter 3.2.. 
 
Analysis of candesartan 
Fifty microliter aliquots of plasma were mixed with 150 μL of an internal standard solution 
(methanol plus 0.01% acetic acid) containing hydrochlorothiazide-13C15N2d2 (100 ng/mL), 
olmesartan-d6 (25 ng/mL), and candesartan-d5 (50 ng/mL), vortex mixed for 30 seconds and 
centrifuged (3,220g for 30 min at 10°C). Ten microliters deproteinized supernatant was injected 
directly into the HPLC–MS/MS system. The analytes were separated on an Atlantis dC18 
analytical column (3 µm, 100 x 2.1 mm, Waters, Massachusetts, USA) using a gradient of water 
(mobile phase A) and acetonitrile (mobile phase A) both supplemented with 0.01% acetic acid. 
The total run time was 3 min. Samples were quantified using peak area ratios. Olmesartan, 
olmesartan-d6, candesartan, candesartan-d5, hydrochlorothiazide, and hydrochlorothiazide-
13C15N2d2 were analyzed using electrospray ionization with multiple reaction monitoring 
(MRM) in negative polarity mode. The applied mass transitions and retention times are 
illustrated in Table 1. The method was linear over a concentration range of 1-500 ng/mL. 
Concentrations were calculated by interpolation from a calibration curve. Quality control 
samples were analyzed throughout the sample analysis. 
 
Analysis of amlodipine, metoprolol, bisoprolol, lercanidipine, and nebivolol 
Fifty microliter aliquots of plasma were mixed with 150 μL of an internal standard solution 
(methanol plus 0.01% acetic acid) containing amlodipine-d4, metoprolol-d6, bisoprolol-d5, 
lercanidipine-d3, and nebivolol-d4 at a final concentration of 10 ng/mL, vortex mixed for 
30 seconds and centrifuged (3,220g for 30 min at 10°C). Fifty microliters deproteinized 
  
87 
supernatant was injected directly into the HPLC–MS/MS system. Samples were concentrated 
and purified on a trap cartridge (EXP HALO C18, 4.6 x 5 mm, Optimizetechnologies, Oregon, 
USA) at a flow rate of 3 mL/min acetonitrile and water (80:20 v/v) supplemented 0.01% acetic 
acid. The analytes were separated on an Atlantis dC18 analytical column (3 µm, 100 x 2.1 mm, 
Waters, Massachusetts, USA) using a gradient of water (mobile phase A) and acetonitrile 
(mobile phase A) both supplemented with 0.01% acetic acid. The total run time was 3.5 min. 
Samples were quantified using peak area ratios. The analytes were analyzed using electrospray 
ionization with multiple reaction monitoring (MRM) in positive polarity mode. The applied mass 
transitions and retention times are illustrated in Table 1. The method was linear over a 
concentration range of 0.1-50 ng/mL for nebivolol and lercanidipine, and over 1-500 ng/mL for 
metoprolol, bisoprolol, and amlodipine. Concentrations were calculated by interpolation from a 
calibration curve. Quality control samples were analyzed throughout the sample analysis. 
 
Quantification of RAS Peptide Concentrations 
RAS peptide concentrations were quantified as described in chapter 3.2.. 
Table 1   
Analyt MRM [m/z] Retention time [min] 
Perindoprilat 339.1 → 167.8  1.04 
Perindoprilat-d4 343.1 → 167.8  
Candesartan 439.2 → 308.8 1.85 
Candesartan-d5 444.2 → 309.1  
Hydrochlorothiazide 295.9 → 204.7 1.01 
Hydrochlorothiazide-13C15N2d2 301.1 → 207.7  
Olmesartan 445.2 → 148.9 1.34 
Olmesartan-d6 451.2 → 153.9  
Metoprolol 268.3 → 116.1 1.28 
Metoprolol-d6 274.3 → 122.0  
Bisoprolol 326.4 → 116.0 1.41 
Bisoprolol-d5 331.4 → 121.1  
Amlodipine 409.1 → 294.0 1.53 
Amlodipine-d4 413.1 → 297.9  
Nebivolol 406.1 → 150.9, 103.1, 123.1 1.55 
Nebivolol-d4 410.2 → 151.0  
Lercanidipine  612.4 → 100.3, 280.0 1.84 
Lercanidipine-d3 615.4 → 283.2  
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Statistical analysis 
No statistical analysis was performed. Data were described descriptively. 
 
 
Results 
Patients 
A subgroup of 10 patients with uncontrolled hypertension recruited between October 2016 and 
December 2016 was evaluated.  
Table 2. Demographics and patient characteristics (N = 10).  
Sex  
Male 8 (80%) 
Female 2 (20%) 
Age, years 56 (28 – 82) 
BMI, kg/m
2
 31 (28 – 38) 
Ethnicity  
Caucasian 9 (90%) 
Black 1 (10%) 
Ambulatory Daytime BP  
SBP, mmHg 144 (130 – 162) 
DBP, mmHg 79 (71 – 92) 
Heart rate, bmp 84 (52 – 98) 
Antihypertensive drugs (n) 4 (3 – 5) 
Diuretic 90% (90%) 
ACE inhibitor / Angiotensin receptor antagonist 40% (40%) / 60% (60%) 
Calcium channel antagonist 10 (100%) 
Beta-receptor antagonist 6 (60%) 
Alpha-receptor antagonist 2 (20%) 
Co-Medication  
Proton pump inhibitor 5 (50%) 
Antidiabetic 5 (50%) 
Lipid lowering agent 5 (50%) 
Platelet aggregation inhibitor 6 (60%) 
Data are presented as number (percentage) for categorical variables and 
median (range) for continuous variables. 
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All patients presented with a documented history of uncontrolled hypertension under their 
respective antihypertensive therapy. Patients included in the subgroup were 8 men and 
2 women from 28 to 82 years, and their body mass index ranged between 28 and 38 kg/m2. 
Nine patients were of Caucasian ethnicity and one subject was of African descent. Ambulatory 
blood pressure monitoring revealed an average systolic blood pressure of 144 mmHg and a 
mean diastolic blood pressure of 79 mmHg. Patients used tolerated doses of 4 antihypertensive 
drugs on average (range 3 to 5), including a diuretic in every patient. One patient was excluded 
from evaluation because of a lack of fulfilling the inclusion criteria of inclusion of a diuretic in 
antihypertensive drug treatment. Detailed patient characteristics at time of inclusion are 
presented in Table 2. 
 
Plasma drug concentrations and blood pressure 
Ambulatory blood pressure at first visit (random time after drug intake) as well as before and 
4 hours after observed drug intake (n = 9). Antihypertensive drugs of evaluated patients are 
listed in Table 3.  
 
Table 3. Antihypertensive treatment. 
Subject Diuretic ARB ACE CCB B-Blocker 
TRHT-001 Hydrochlorothiazide* Candesartan* - Amlodipine - 
TRHT-002 Indapamide* - Perindopril* Amlodipine* - 
TRHT-003 Indapamide* - Perindopril* Lercanidipine Bisoprolol 
TRHT-004 Hydrochlorothiazide* Olmesartan* - Amlodipine* - 
TRHT-006 Indapamide* - Perindopril* Amlodipine* Nebivolol 
TRHT-007 Hydrochlorothiazide* Olmesartan* - Amlodipine* Metoprolol 
TRHT-008 Hydrochlorothiazide* Candesartan* - Lercanidipine Bisoprolol 
TRHT-009 
 
Chlortalidon*, 
Torasemide 
Azilsartan* 
 
Lercanidipine Metoprolol 
TRHT-010 Hydrochlorothiazide* Olmesartan* - Amlodipine* Metoprolol 
* given as fixed drug-combination 
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Plasma concentrations of perindoprilat, olmesartan, candesartan, amlodipine and 
hydrochlorothiazide at a random time point as well as before and after observed drug intake are 
shown in Figure 1. 
 
 Figure 1. Plasma concentrations of patients 
at first clinic visit (random time point x) and 
plasma concentrations before and 4 hours 
after observed drug intake () of A) 
perindopril, B) olmesartan, C) candesartan, 
D) amlodipine and E) hydrochlorothiazide. 
Expected plasma concentrations and tmax of 
respective drugs are indicated as grey boxes and a vertical dotted line, respectively. 
 
One patient showed at random time point a partial non-adherence for combined preparation of 
hydrochlorothiazide and candesartan and possibly also amlodipine. Increased plasma 
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concentration and a decrease of blood pressure from 137/99 mmHg to 121/90 mmHg on day of 
observed drug intake justify a more regular intake of drugs. Blood pressure decreased again 4 
hour after observed drug intake to 114/82 mmHg. In 1 patient with a combined preparation of 
indapamide, perindopril and amlodipine plasma concentrations of indapamide and amlodipine 
were in line with published values, but plasma concentrations of perindopril were low. Assuming 
that the patient was compliant, a drug interaction with food could explain this observation. 
Plasma concentration measurements of the remaining 8 patients confirmed adherence to their 
respective drug treatment. Systolic and diastolic blood pressure decreased in all patients 4 hour 
after observed drug intake, but systolic blood pressure remained ≥ 145 mmHg in 5 of the 
patients. In 2 patients blood pressure decreased to 129/68 mmHg and 118/69 mmHg, 
respectively. Both of these patients were on a four drug combination. Ambulatory blood 
pressure at first visit (random time after drug intake) as well as before and 4 hours after 
observed drug intake are given in Table 4. 
 
Table 4. Ambulatory blood pressure at first visit (random time after drug intake) as well as 
before and 4 hours after observed drug intake (n = 9).  
 
Random time point 
Before 
observed drug intake 
4 h after 
observed drug intake 
SBP (mmHg) 144 (121 – 181) 150 (121 – 186) 147 (118 – 165) 
DBP (mmHg) 83 (68 – 90) 81 (62 – 100) 78 (68 – 90) 
Heart rate (bmp) 69 (53 – 94) 68 (50 – 102) 71 (45 – 98) 
Data are presented as median (range). 
 
Angiotensin peptide concentrations in patients with uncontrolled hypertension 
All patients who had measurable plasma concentrations of an angiotensin receptor antagonist 
showed strongly increased equilibrium Ang 1-10 and Ang 1-8 concentrations (TRHT-001, 
TRHT-004, TRHT-008, and TRHT-009).  Peak concentrations of Ang 1-10 and Ang 1-8 were 
≥ 800 pg/ml and ≥ 2000 pg/ml, respectively, comparable to concentrations observed in patients 
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with primary arterial hypertension on olmesartan monotherapy (NCT02449811). Only the patient 
with azilsartan (TRHT-009) showed a smaller increase of Ang 1-8 (1414 pg/ml) but a 
comparable increase of Ang 1-10 (956 pg/ml). In addition, the increase in Ang 2-8, Ang 1-5 and 
Ang 3-8 observed in normotensive healthy subjects (NCT01771783) and patients with primary 
arterial hypertension (NCT02449811) was observed in patients with uncontrolled hypertension 
as well. Despite almost two-fold olmesartan plasma compared to literature values one patient 
(TRHT-007) did not show characteristic increases of  Ang 1-10 or Ang 1-8 concentrations 
observed after angiotensin receptor blockade. Ang 1-10 or Ang 1-8 concentrations were 
52 pg/ml and 123 pg/ml 4 hours after dosing and also blood pressure remained elevated with 
165/74 mmHg. The patient with no measurable plasma concentration of hydrochlorothiazide 
and very low plasma concentration of candesartan at random visit, showed baseline 
concentrations of Ang 1-10 and Ang 1-8 of 185 pg/ml and 189 pg/ml, respectively, and 
characteristic changes produced by an angiotensin receptor antagonist with Ang 1-10 and 
Ang 1-8 concentrations of 3260 pg/ml and 6188 pg/ml 4 hours after observed drug intake 
(TRHT-001).  
Of the 3 patients with perindopril in their drug combination, only 1 patient (TRHT-002) showed 
the characteristic increase of Ang 1-10 concentrations observed after ACE inhibition in 
normotensive healthy subjects (NCT01771783) and patients with newly diagnosed arterial 
hypertension (NCT02449811). Despite measurable plasma concentrations, in the remaining 
2 patients (TRHT-003 and TRHT-006), Ang 1-10 concentrations were not increased at all, 
neither in the random samples nor on the days after observed drug intake. However, the ratio 
between Ang 1-8 and Ang 1-10 is clearly suppressed, indicating efficient blockade of ACE in 
these patients, while very low renin activity appears to be evident. Interestingly, the only 
difference in drug treatment of these patients compared do the other patient with perindopril 
treatment is a beta-receptor antagonist. Another observation is, that despite a low renin 
hypertension of these 2 patients, 1 patient (TRHT-006) has an aldosterone concentration of up 
to 372 pM, which could indicate primary aldosteronism. Despite a lower aldosterone 
concentration of patient TRHT-003 (147 pM), aldosterone mediated hypertension and resulting 
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suppression of renin cannot be excluded in this patient, as suggested by an elevated 
Aldosterone / Angiotensin II ratio. Bubble plot schemes of RAS peptide concentrations of every 
patient with uncontrolled hypertension before and 4 hours after observed drug intake are given 
in Figure 2. 
 TRHT-001 TRHT-002 TRHT-003 TRHT-004 
Before 
observed 
drug intake 
    
4 h after 
observed 
drug intake 
 
   
 TRHT-006 TRHT-007 TRHT-008 TRHT-009 
Before 
observed 
drug intake 
    
4 h after 
observed 
drug intake 
 
   
Figure 2. Bubble plot schemes of ex vivo equilibrium RAS peptide concentrations before and 
4 hours after observed drug intake. The diameter of the bubble corresponds to the concentration 
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(pg/ml). The numeric value of the concentration is given below the peptide designation according to the 
number of amino acids in parenthesis. The arrows designate known degradation pathways with the 
responsible enzymes. ACE, angiotensin converting enzyme; AP, aminopeptidase A; DAP, dipeptidyl 
aminopeptidase; NEP, neutral endopeptidase. 
 
Ang 1-8 / Ang 1-10 ratios as a marker for ACE activity are shown in Figure 3. Before observed 
drug intake, mean Ang 1-8 / Ang 1-10 ratios were 2.2 (sd 0.6) and 0.2 (sd 0.1) for the 
angiotensin receptor antagonists and the ACE inhibitor, respectively. After observed drug intake 
mean Ang 1-8 / Ang 1-10 ratios were 1.8 (sd 0.5) and 0.1 (sd 0.1) for the angiotensin receptor 
antagonists and the ACE inhibitor, respectively. Calculated with Ang 1-8 and Ang 1-10 
concentrations at a random time point mean Ang 1-8 / Ang 1-10 ratios differed with 2.1 (sd 1.3) 
and 0.1 (sd 0.1) for the angiotensin receptor antagonists and the ACE inhibitor, respectively 
(Figure 3). 
 
Figure 3. Ratios of equilibrium levels of the 
ACE product Ang 1-8 and the ACE substrate 
Ang 1-10 before and 4 hours after observed 
drug intake of a multiple antihypertensive drug 
treatment including an angiotensin receptor 
antagonist (white boxes) or an ACE inhibitor 
(grey boxes) and at a random time point. 
 
 
Discussion 
In this study we quantified equilibrium concentrations of different renin-angiotensin system 
peptides in patients with uncontrolled hypertension. Concentrations were measured once 
together with routine blood sampling at a clinical check-up visit (random time point) as well as 
before and 4 hours after a planned observed drug intake. Concentrations of Ang 1-10 and 
Ang 1-8 could be quantified in all study participants. Pharmacokinetic analyses showed 
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antihypertensive drug concentrations compatible with drug intake prior to the clinic visit in all but 
one patient, who did not have measurable concentrations of his antihypertensive combination 
drug (hydrochlorothiazide and candesartan), compatible with partial non-adherence to his triple 
drug regimen. Treatments including the ACE inhibitor perindopril or angiotensin receptor 
antagonists (olmesartan and candesartan) lead to characteristic changes of RAS peptide 
concentrations which were previously observed in normotensive healthy subjects 
(NCT01771783) and in patients with newly diagnosed arterial hypertension (NCT02449811) on 
monotherapy. Azilsartan showed a less pronounced effect on Ang 1-8 compared to olmesartan, 
although Kurtz and Kajiya (2012) [10] showed it to be more potent in inhibiting binding of 
angiotensin II to human angiotensin II type 1 receptor membrane preparations compared to 
olmesartan and candesartan. Quantification of RAS peptide concentrations after monotherapy 
drug treatment with azilsartan and candesartan might indicate whether differences in 
angiotensin receptor affinity lead to differences in Ang 1-10 and Ang 1-8 increase. However, it is 
questionable whether differences in receptor affinity really would be reflected in RAS 
concentrations in serum. 
Two patients treated with a combination of an ACE inhibitor (perindopril) and a beta-receptor 
antagonist (bisoprolol / nebivolol) did not show an increase of Ang 1-10 concentrations typically 
seen after ACE-inhibitor monotherapy. This might reflect the effect of beta-receptor antagonists 
which cause a reduction of renin secretion [11], but might also be contributed to a state of 
primary aldosteronism, which is supported by elevated aldosterone levels and an elevated 
Aldosterone / Angiotensin II ratio. In contrast to bisoprolol, nebivolol also has vasodilatory 
properties presumably by NO-modulation, this however, did not lead to a detectable difference 
in RAS peptide profiles. 
Ang 1-7 was quantifiable in all patients except in patients with low renin hypertension 
(TRHT-003, TRHT-006, and TRHT-007). An increase of Ang 1-7 after ACE inhibitor treatment 
was observed in normotensive healthy subjects (NCT01771783) and in patients with newly 
diagnosed arterial hypertension started on monotherapy (NCT02449811). 
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The ratio of the ACE product Ang 1-8 and the ACE substrate Ang 1-10 can be used as a marker 
of ACE activity. RAS peptide profiles could qualify as a surrogate marker of drug adherence to 
an angiotensin receptor antagonist and ACE inhibitor also in patients with drug combinations 
and based on the equilibrium Ang 1-8 / Ang 1-10 ratio, ACE inhibition can also be monitored if 
the characteristic renin feedback mediated increase of angiotensin concentrations is not 
observed. 
Two patients underwent renal denervation after the end of study visit. Further assessments of 
RAS peptide profiles before and after renal denervation may provide more information about the 
impact of the local renal RAS system on measured RAS peptide concentration. 
 
The strength of our study lies in the comprehensive assessment of angiotensin peptides using a 
mass spectrometry based approach, known to provide high quality angiotensin data. The 
simultaneous analysis of multiple angiotensin metabolites in a single sample provided additional 
information in terms of general activity of the RAS in individual patients and revealed drug 
treatment specific differences in enzyme activities (Ang 1-8 / Ang 1-10 ratio), which could be 
identified as a surrogate for ACE activity by using this multiplex approach. 
The small sample size and considering the big variety in drug combinations are limitations of 
our study that do not allow a conclusion of unclear findings such as the effect of azilsartan 
compared to olmesartan and candesartan or the impact of a combination of an ACE inhibitor 
with a beta-receptor antagonist. 
 
In conclusion we have shown that in patients with uncontrolled hypertension and combined drug 
treatment for a long period of time, the characteristic changes of angiotensin peptide profiles 
induced by an ACE inhibitor or an angiotensin receptor antagonist monotherapy, are maintained 
even in patients treated with antihypertensive combination drug regimens. 
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4 Discussion and Conclusions 
The thesis describes RAS peptide concentrations in healthy subjects and in patients 
with a new diagnosis of primary arterial hypertension. Furthermore, the thesis 
presents changes in RAS peptide concentrations after multiple dose administration 
of different RAS inhibitors in these conditions and changes in RAS peptide 
concentrations after multiple dose administration of different non-RAS inhibitors 
used for the treatment of arterial hypertension. Finally, the thesis presents RAS 
peptide concentrations in patients with uncontrolled hypertension treated with a 
drug combination of RAS inhibitors and drugs without direct pharmacologic 
effects on the RAS. 
Our studies show that different RAS inhibitors produce characteristic 
changes of RAS peptide profiles in normotensive healthy subjects as well as in 
patients with arterial hypertension. The changes directly reflect the mechanisms of 
action of the investigated RAS inhibitors. After multiple dose monotherapy we can 
distinguish between treatment with an angiotensin receptor antagonist and an ACE 
inhibitor by measurement of plasma Ang 1-10 and Ang 1-8 concentration. The 
characteristic changes of an angiotensin receptor antagonist and an ACE inhibitor 
are reflected in the Ang 1-8/Ang 1-10 ratio. After ACE inhibition the ratio is low 
(indicating low ACE activity), after angiotensin receptor blockade, the ratio is 
higher (indicating non-inhibited ACE activity) comparable to control samples. In 
addition, data from the third project provide evidence that it is even possible to 
detect the effects of an angiotensin receptor antagonist or an ACE inhibitor in 
patients with uncontrolled hypertension treated with a combination of 
antihypertensive drugs. Interestingly, RAS activity appeared to be very low in a 
portion of patients as reflected by low to undetectable angiotensin levels. 
Depending on the patient cohort analyzed, there are multiple possible explanations 
for low renin activity. Patient specific variations, certain anti-hypertensive drugs 
(e.g. beta-receptor antagonists) or disease states (e.g. primary aldosteronism) are 
known to result in renin suppression, however, higher patient numbers would be 
required to draw definitive conclusions in our patient cohorts. Calcium channel 
antagonists and hydrochlorothiazide produce changes of RAS peptides similar (but 
less pronounced) to the pattern observed after an angiotensin receptor antagonist. 
However, if they are combined with an ACE inhibitor, the low Ang 1-8 / Ang 1-10 
ratio typical for ACE inhibitor treatment remains detectable. 
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Over all, data generated by these studies showed a correlation between RAS 
peptide concentrations and treatment with an ACE inhibitor or angiotensin receptor 
antagonist in normotensive healthy subjects and in patients with arterial 
hypertension, as well as in patients with uncontrolled hypertension treated with a 
combination drug regimen. Our data indicate that RAS peptide profiles merit 
further investigations as a biomarker for the assessment of adherence and (in 
combination with drug concentrations in plasma) possibly true drug resistance, and 
that they also may provide guidance for the treatment of patients with difficult to 
control arterial hypertension. Whether RAS peptide profiles will also be of use in 
patients with other cardiovascular diseases treated with RAS inhibitors (e.g. heart 
failure) remains to be shown in subsequent studies. 
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Outlook 
The anticipated study end for the two ongoing research projects, the clinical trial 
investigating RAS peptides in patients with arterial hypertension and the study 
investigating RAS peptides in patients with uncontrolled hypertension, will be in 
the third or fourth quarter 2017. Final data evaluation will show whether the 
preliminary results can be confirmed. Investigation of RAS peptide profiles in 
patients with isolated diastolic hypertension will start even before the anticipated 
end of the two ongoing clinical studies mentioned above. In subsequent studies 
RAS peptide profiles will be assessed in other patient populations treated with the 
same drug groups as patients with arterial hypertension (e.g. patients with heart 
failure) where differentiation between “drug resistance” and adherence related 
problems is of similar interest. In addition, quantification of RAS peptide 
concentrations offers many additional interesting applications, e.g. assessment of 
hyperaldosteronism, where the use of the Aldosterone / Angiotensin II ratio instead 
of the classic Aldosterone / Renin ratio may offer advantages such as lower 
variability and reduced interference by concomitant drug treatment (e.g. ACE 
inhibitors). 
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